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I.P                                -    Indian Pharmacopeia 
 
 
IR                                 -    Infrared Spectroscopy 
 
 
IUPAC                         -    International Union of Pure and Applied Chemistry 
 
 
LC                                -    Liquid Chromatography 
 
 
LC-MS                         -    Liquid Chromatography-Mass Spectroscopy 
 
 
LOD                             -    Limit of detection 
LOQ                             -    Limit of quantitation 
NMT                            -    Not more than 
Nm                               -    Nanometer 
NLT                             -    Not less than 
M                                 -    Molar 
Max                              -    Maximum 
mg                                -    Milligram 
 Min                              -    Minute 
 
 
Ml                                -    milli litres 
 
 
Mm                              -    millimetre 
 
 
M.W                            -    Molecular weight 
ODS                             -    Octyl decyl silane 
Ppm                             -    Parts Per Million 
RSD                             -    Relative Standard Deviation 
 
 
RP-HPLC                    -    Reverse Phase High Performance Liquid Chromatography 
 
 
S.D                               -    Standard Deviation 
 
 
TLC                             -    Thin Layer Chromatography 
tR                                                   -    Retention time 
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US FDA                       -    United States Food and Drug Administration 
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UV                               -    Ultra-Violet 
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1.  INTRODUCTION 
 
 
Analytical chemistry is concerned with the determination of the chemical 
composition of matter qualitatively and quantitatively. It is the multidisciplinary 
branch of science. Analytical chemistry has got extensive applications in various 
disciplines of chemistry such as inorganic, organic, and physical and 
biochemistry.Related sciences such as environmental science, agricultural science, 
oceanography, forensic science have the application of analytical chemistry. For 
instances monitoring of environmental pollutants like SO2, CO, CO2     is done by 
flurosecence or infrared spectroscopy.Analysis of dissolved oxygen and chlorine in 
water is carried out by potentiometry or colorimetry. (S. M. Khopkar, 2008). 
 
Analytical chemistry has got a pivot role to play in determination of quality 
of medicines as quality is important and essential aspect to be considered in every 
product or service. Quality is more vital in medicines as it is related to life. A 
compromise in pharmaceutical quality is nothing but playing with the life of 
consumer. Application of analytical chemistry in pharmacy is termed as 
pharmaceutical analysis. The terms quality, quality control, qualityassuarance, total 
quality management are correlated. The ultimate goal of all these is to provide a 
product with good quality, safety, efficiency, purity, strength and identity. (Devis 
John, 1999). 
 
General terms associated with chemical analysis 
 
 
  Analytical technique 
 
 
It  is  the  fundamental  scientific  phenomenon  that  is  proved  useful  for 
providing information on the composition of substances. 
 
  Analytical method 
 
 
The method is the specific application of technique to solve the analytical 
problem. 
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  Protocol 
 
 
The most specific description of a method is known as protocol. 
 
 
  Procedure 
 
 
A procedure is written instructions for carrying out a method. The “standard 
methods” developed by the ASTM (American Society for Testing Materials) 
and  the  AOAC  (Association  of  Official  Analytical  Chemists).  It  only 
provides the general steps to be followed. (Willard et al., 1986.) 
 
Pharmaceutical analysis is broadly classified into two branches, namely 
qualitative analysis and quantitative analysis. 
 
A.  Qualitative analysis: It deals with the    identification and establishment of 
the identity of analyte among elements or compounds present in the sample. 
 
B.  Quantitative analysis: It deals with the quanification of the analyte present 
in the matter of sample. (S. Ravi Shankar, 2006). 
 
The determination of the quality and of quantity of the sample is done the 
application of analytical methods. 
 
Analytical methods are classified into two types 
 
 
  Instrumental methods. 
 
 
  Non-instrumental methods. 
 
 
Non – instrumental methods of analysis 
 
 
The physico-chemical properties are utilised in these methods of analysis to 
determine the contents or the composition of the substance. (Dr. A. V. Kasture and 
et al., 2010) 
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Table No: 1.1 Classification of Non-instrumental methods (S. M. Khopkar, 2008) 
 
 
S.No. Method of analysis Physico – chemical 
 
property 
1 Volumetric analysis(acid- 
 
base titrations) 
Neutralisation reaction 
2 Redox titrations Oxidation and reduction 
 
reactions 
3 Complexometric titrations Formation of complex 
4 Solvent extraction Extraction 
5 Gravimetric analysis Measurement of the 
 
weight precipitated. 
 
 
 
Instrumental methods 
 
 
The physical properties of the components are considered in these methods 
of analysis. 
 
Analytical instrumentation plays an important role in production and 
evaluation of new products. The instrumentation provides lower detection limits 
which are required to assure safety, efficacy and quality of product of interest. 
(Willard et al.1986.) 
 
Instruments used in chemical analysis do not give direct quantitative data but 
supplies information which is converted into suitable form which correlates with 
structure or content. 
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The instrument does the job in various steps which are as follows 
 
 
  Generation of signal 
 
 
  Transformation of signal into measurable form 
 
 
  Amplification 
 
 
  Presentation of signal (Read out system) (Dr. A. V. Kasture and et al., 2010). 
 
 
In some instrumental procedures the sample is destroyed (destructive 
methods), where as in others it remains unchanged(non –destructive)and may be 
used in subsequent studies. 
 
The choice of an instrumental procedure for the determination of a specific 
element or compound really involves two choices: 
 
1)  Instrument to be used. 
 
 
2) The chemical system (Gurudeep R. Chatwal and Sham K. Anand, 2008) 
 
 
Advantages of instrumental methods 
 
 
  A small amount of asample is sufficient for analysis. 
 
 
  Determination is considerably fast. 
 
 
  Complex mixture can be analysed with or without separation 
 
 
  Precise, accurate, reliable results are obtained. 
 
 
 
 
 
Limitation of instrumental methods 
 
 
  Instrumental methods are expensive. 
 
 
  Requirement of trained personnel for handling of instruments. 
 
 
  Instrumental methods may not be specific. 
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  Sensitivity and accuracy depends upon the type of instrument. 
 
 
  Frequent  checking of results  is  necessary.  (Dr.  A.  V.  Kasture and  etal., 
 
2010). 
 
 
Classification of instrumental analysis 
 
 
  Molecular analysis. 
 
 
  Elemental analysis. 
 
 
Principle types of chemical instrumentation 
 
 
  Spectroscopic techniques. 
 
 
  Electrochemical techniques. 
 
 
  Chromatographic techniques 
 
 
  Miscellaneous techniques 
 
 
  Hyphenated techniques. (Gurudeep R. Chatwal and Sham K. Anand, 2008), 
(Willard et al., 1986.) 
 
Table No: 1.2 Different types of Instrumental methods 
 
 
S. No Instrumental 
 
Technique 
Instrumental Method Physical 
property 
1 Spectroscopy UV-visible 
 
spectrophotometry 
Absorption and 
 
emission of 
radition 
Florescence and 
 
phosphorescence 
spectrophotometry 
Emission of 
 
radiation 
Infra red Absorption of 
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  spectrophotometry radiation 
Raman spectroscopy Scattering of 
 
radiation 
x-ray spectroscopy Diffraction of 
 
radiation 
Radio chemical 
 
techniques 
Radio activity 
Nuclear magnetic 
 
resonance 
Absorption of 
 
radiation 
Electron spin 
 
resonancespectroscopy 
Absorption of 
 
radition 
Atomic spectrometry 
 
 
(emissionand 
absorption) 
Emission and 
 
absorption of 
radiation 
2 Electrochemical Potentiometry Electrical 
 
potential 
Polarography Electrical current 
Amperometric 
 
techniques 
Electrical current 
Coulometry Quantity of 
 
electricity 
Electrogravimetry Electrical 
 
potential 
Conductance Conductivity 
Chapter-1 Introduction 
Dept. of Pharmaceutical Analysis J.K.K . Nattraja College Of Pharmacy 
7 
 
 
 
 
 
 
3 Chromatographic Gas chromatography Partition 
High performance of 
 
liquid chromatography 
Adsorption or 
 
partition 
4 Miscellaneous Thermal analysis Thermal 
 
properties 
Mass spectroscopy Mass to charge 
 
ratio 
Refractometry and 
 
interferometry. 
Refraction of 
 
radiation 
Polarimetry Rotation of 
 
radiation 
Circular dichorism Rotation of 
 
radiation 
5 Hyphenated GC – MS Partition and mass 
 
to charge ratio 
GC – IR Partition and 
 
absorption of 
radiation 
ICP – MS Mass to charge 
 
ratio 
MS - MS Mass to charge 
 
ratio 
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  Major steps in analytical method development (Willard et al., 1986.) 
 
 
Evaluation of problem 
 
 
 
 
Literature survey regarding 
the sample 
 
 
 
Selection appropriate methods 
 
 
 
 
 
Obtain and store sample 
 
 
 
 
Pre-treatment of sample 
 
 
 
 
Perform required measurements 
 
 
 
 
 
Compare results with standard 
 
 
 
 
Apply necessary statistical 
methods 
 
 
 
Present results in the form 
understandable to analyst 
 
 
 
 
Present results to customer 
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Types of errors 
 
 
  Random (indeterminate) Errors. 
 
 
  Systematic (determinate) Errors. (Willard et al., 1986.) 
 
 
 
 
CHROMATOGRAPHY 
 
 
 
The term Chromatography (in Greek, khromatos means colour and Graphos 
means written) means colourwriting. The term chromatography and its principles 
were discovered  in  1903  by Mikhiltswett.  Chromatography is  the separation  of 
mixture of components into individual components by using a stationary phase and a 
mobile phase. (B.K. Sharma, Chromatography, 2007) 
Chromatography is method of separating mixtures and identifying their 
components i.e. it’s a separation method that exploits the differences in partitioning 
behaviour of analyse between a mobile phase and a stationary phase to separate 
components in a mixture. Components of a mixture may be interacting with the 
stationary phase based on charge (ion-ion-interactions, ion-dipole-interactions), 
Vander Waal’s forces, relative solubility or adsorption (hydrophobic interactions, 
specific affinity). 
 
Chromatography may be preparative or analytical. Preparative 
chromatography seeks to separate the components of a mixture for further use (and 
is thus a form of purification). Analytical chromatography normally operates with 
smaller  amounts  of  material  and  seeks  to  measure  the  relative  proportions  of 
analytes in a mixture. The two are not mutually exclusive. 
 
Classification of chromatographic methods 
 
    Gas – solid chromatography. 
 
    Gas – liquid chromatography. 
 
    Solid – liquid chromatography. 
 
    Liquid- liquid chromatography. (B.K. Sharma, Chromatography, 2007 
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HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
 
 
 
High-performance liquid chromatography (HPLC) is the fastest growing 
analytical technique for analysis of drugs. Its simplicity, high specificity and wide 
range of sensitivity make it ideal for the analysis of many drugs in both dosage 
forms and biological fluids. 
 
The HPLC offers the following advantages. 
 
 
  Speed (many analysis can be accomplished in 20 min or less). 
 
 
  Greater sensitivity (various detectors can be employed). 
 
 
  Improved resolution (wide variety of stationary phases). 
 
 
  Reusable columns (expensive columns but can be used for many analysis). 
 
 
  Ideal for the substances of low viscosity. 
 
 
  Easy sample recovery, handling and maintenance. 
 
 
  Instrumentation leads itself to automation and quantification (less time and 
less labour). 
 
  Precise and reproducible. 
 
 
  Integrator itself does calculations. ( P.D.Sethi, 2001) 
 
 
Applications of HPLC 
 
 
    To purify synthetic or natural products 
 
    To characterize metabolites 
 
 To   assay  active  ingredients,   impurities,  degradation   products   and   in 
dissolution assays 
    In pharmacodynamics and pharmacokinetic studies 
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TYPES OF HPLC TECHNIQUES 
 
 
Based on modes of chromatography 
 
  Normal phase chromatography 
 
  Reverse phase chromatography 
 
Based on principle of separation 
 
  Adsorption chromatography 
 
  Ion exchange chromatography 
 
  Size exclusion chromatography 
 
  Affinity chromatography 
 
  Chiral phase chromatography 
 
Based on elution technique 
 
  Isocratic separation 
 
  Gradient separation 
 
Based on the scale of operation 
 
  Analytical HPLC 
 
  Preparative HPLC 
 
 
PRINCIPLES OF SEPARATION 
 
 
Adsorption chromatography employs high-surface area particles that adsorb 
the solute molecules. Usually a polar solid such as a silica gel, alumina or porous 
glass beads and a non-polar mobile phase such as heptane, octane or chloroform are 
used in adsorption chromatography. In adsorption chromatography, adsorption 
process is described by competition model and solvent interaction model. 
 
In  partition  chromatography,  the  solid  support  is  coated  with  a  liquid 
stationary phase. The relative distribution of solutes between the two liquid phases 
determines the separation. The stationary phase can either be polar or non polar. If the 
stationary phase is polar and the mobile phase is non polar, it is called normal phase 
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partition  chromatography.  If  the  opposite  case  holds,  it  is  called  reverse-phase 
partition chromatography. In normal phase mode, the polar molecule partition 
preferentially in to the stationary phase and are retained longer than non-polar 
compounds. In reverse phase partition chromatography, the opposite behavior is 
observed.( Willard et al., 1986) 
 
 
INSTRUMENTATION OF HPLC 
Figure no 1.1 typical diagram of HPLC 
 
 
 
 
 
 
 
 
 
SOLVENT   DELIVERY   SYSTEM   (B.K.Sharma,   Instrumental   methods   of 
chemical analysis, 2005) 
 
The mobile phase is pumped under pressure from one or several reservoirs 
and flows through the column at a constant rate. With micro particulate packing, 
there is a high-pressure drop across a chromatography column. Eluting power of the 
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mobile phase is determined by its overall polarity, the polarity of the stationary 
phase and the nature of the sample components. For normal phase separations, 
eluting power increases with increasing polarity of the solvent but for reversed phase 
separations, eluting power decreases with increasing solvent polarity. Optimum 
separating conditions can be achieved by making use of mixture of two solvents. 
Some other properties of the solvents, which need to be considered for a successful 
separation,  are  boiling  point,  viscosity,  detector  compatibility,  flammability and 
toxicity. 
 
The most important component of HPLC in solvent delivery system is the 
pump, because its performance directly effects the retention time, reproducibility 
and detector sensitivity. 
 
Types of pumps in HPLC 
 
 
1.   Syringe pump (screw driven) 
 
2.   Reciprocating pump 
 
- Single piston reciprocating pump 
 
- Dual piston reciprocating pump 
 
- Reciprocating diaphragm pump 
 
3.   Pneumatic pump 
 
- Direct pressure pump 
 
- Amplifier pump 
 
Among the several solvent delivery systems, (direct gas pressure, pneumatic 
intensifier,  reciprocating  etc.)  reciprocating  pump  with  twin  or  triple  pistons  is 
widely used, as this system gives less baseline noise, good flow rate reproducibility 
etc. 
 
MOBILEPHASE 
 
 
Mobile phases used for HPLC typically are mixtures of organic solvents and 
water or aqueous buffers. The following points should also be considered when 
choosing a mobile phase 
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1.   It is essential to establish that the drug is stable in the mobile phase for at 
least the duration of the analysis. 
 
2.   Excessive salt concentrations should be avoided. High salt concentrations 
can result in precipitation, which can damage HPLC equipment. 
 
3.   The mobile phase should have a pH 2.5 and pH 7.0 to maximise the life time 
of the column. 
 
4.   Reduce cost and toxicity of the mobile phase by using methanol instead of 
acetonitrile when possible. 
 
5.   Minimise the absorbance of buffer. Since trifluoroacetic acid, acetic acid or 
formic acid absorb at shorter wavelengths, they may prevent detection of 
products with outchromophores above 220 nm. Carboxylic acid modifiers 
can be frequently replaced by phosphoric acid, which does not absorb above 
200 nm. 
 
 
6.   Use volatile mobile phases when possible, to facilitate collection of products 
and LC-MS analysis. Volatile mobile phases include ammonium acetate, 
ammonium  phosphate,  formic  acid,  acetic  acid,  and  trifluoroacetic  acid. 
Some caution is needed as these buffers absorb below 220 nm. 
 
Table No: 1.3 
 
 
PHYSICAL PROPERTIES OF COMMON HPLC SOLVENTS 
 
 
Solvent MW BP RI 
 
(25oC) 
UV 
 
 
Cut-off 
 
(nm) 
Density 
 
g/ml 
 
 
(25oC) 
Viscosity 
 
cP 
(25oC) 
Dielectric 
 
 
Constant 
Acetonitrile 41.0 82 1.342 190 0.787 0.358 38.8 
Dioxane 88.1 101 1.420 215 1.034 1.26 2.21 
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Ethanol 46.1 78 1.359 205 0.789 1.19 24.5 
Ethyl 
 
acetate 
88.1 77 1.372 256 0.901 0.450 6.02 
Methanol 32.0 65 1.326 205 0.792 0.584 32.7 
CH2Cl2 84.9 40 1.424 233 1.326 0.44 8.93 
Isopropanol 60.1 82 1.375 205 0.785 2.39 19.9 
n-propanol 60.1 97 1.383 205 0.804 2.20 20.3 
THF 72.1 66 1.404 210 0.889 0.51 7.58 
Water 18.0 100 1.333 170 0.998 1.00 78.5 
 
 
SOLVENT DEGASSING SYSTEM 
 
 
The constituents of the mobile phase should be degassed and filtered before 
use. Several methods are employed to remove the dissolved gases in the mobile 
phase. They include heating and stirring, vacuum degassing with an aspirator, 
filtration through 0.45µ m filter, vacuum degassing with an air-soluble membrane, 
helium purging ultra sonification, purging or combination of these methods. HPLC 
systems are also provided an online degassing system, which continuously removes 
the dissolved gases from the mobile phase. 
 
COLUMNS 
 
 
The heart of the HPLC system is the column. The choice of column packing 
material and mobile phases depends on the physical properties of the drug. Many 
different reverse phase columns will provide excellent specificity for any particular 
separation. It is therefore best to routinely attempt separations with a standard C8 or 
C18 column and determine if it provides good separations. If this column does not 
provide good separation or the mobile phase is unsatisfactory, alternate methods or 
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columns should be explored. In Normal phase mode it contains Silanolgroups 
(hydroxyl). Reverse phase columns differ by the carbon chain length, degree of end 
capping and percent carbon loading. Reverse phase mode contains the following 
groups 
 
C18 - Octadecylsilanecolumn (ODS) 
C8 - Octyl column 
C4 - Butyl column 
CN - Cyano column 
NH2 - Amino column 
SAMPLE INTRODUCTION SYSTEM 
 
 
Two  means  for  analyte  introduction  on  the  column  are  injection  into  a 
flowing stream and a stop flow injection. These techniques can be used with a 
syringe or an injection  valve. Automatic injector is a microprocessor-controlled 
version of the manual universal injector. Usually, up to 100 samples can be loaded 
in to the auto injector tray. The system parameters such as flow rates, gradient, run 
time, volume to be injected, etc. are chosen, stored in memory and sequentially 
executed on consecutive injections. 
 
DETECTORS 
 
 
Detectors used depend upon the property of the compounds to be separated. 
Optical detectors are most frequently used. 
 
 UV-Ultraviolet Detector: The most commonly used detector in LC is the 
ultraviolet absorption detector. Two types of detectors are available. One is a 
fixed wavelength detector which operates at 254nm where most drug 
compounds absorb. The other is variable wavelength detector which can be 
operated from 190 to 600nm 
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 RI – Refractive Index (Universal analyte detector): Solvent must remain 
the same throughout separation. Very temperature sensitive. Sometimes 
difficult to stabilize baseline. 
 
 FD – Fluorescence detector: Excitation wavelength generates fluorescence 
emission at a higher wavelength. Analytes must have fluorophore group. 
Sensitive and selective. Results dependent upon separation conditions. 
 
 MS – Mass Spectroscopic detector: Mass to  charge ratio (m/z) allows 
specific compound identification. Several types of ionization techniques 
include electro spray, atmospheric pressure chemical ionization, electron 
impact. The detector usually contains low volume cell through which the 
mobile phase passes carrying the sample components. 
 
 PDA - Photo Diode Array Detector: This is recent one which is similar to 
UV detector which operates from 190-600nm. Radiations of all wavelengths 
falls on detector simultaneously. The resulting spectra is a 3D or a three 
dimensional plot of response time and wavelength. 
 
 Conductivity Detector: Based on electrical conductivity, the response is 
recorded. The detector is used when the compounds have conducting ions 
like anions and cations. 
 
 Amperometric  Detector:  This  detector  is  used  when  compounds  have 
functional groups which can be either oxidized or reduced. The diffusion 
current recorded is directly proportional to concentration of compound to be 
eluted. 
 
INJECTORS 
 
 
Sample introduction can be accomplished in various ways. The simplest 
method is to use an injection valve. In more sophisticated LC systems, automatic 
sampling devices are incorporated where sample introduction is done with the help 
of auto samplers and microprocessors. 
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In liquid chromatography, liquid samples may be injected directly and solid 
samples need to be dissolved in an appropriate solvent. The solvent need not be the 
mobile phase, but frequently it is judiciously chosen to avoid detector interference, 
column/component interference and loss in efficiency. It is always best to remove 
particles from the sample by filtering or centrifuging since continuous injections of 
particulate material will eventually cause blockage of injection devices or columns. 
 
Sample sizes 
 
 
Typical sample mass with 4.6 mm ID columns range from the nanogram 
level up to about 2 mg diluted in 20 ml of solvent.  In general, it should be noted that 
much less sample preparation is required in LC than in GC since unwanted or 
interfering compounds or both, may often be extracted, or eliminated, by selective 
detection. 
 
STATISTICAL PARAMETERS 
Linear regression 
Once linear relationship has been shown to have a high probability by the 
value of the correlation coefficient ‘r’ then the best straight line through the data 
points has to be estimated. This can be often done by visual inspection of graph 
but in many cases it is far more sensible to evaluate the best straight line by linear 
regression. 
 
Equation of Straight line 
y = mx + c 
Where, ‘y’, the dependent variable was plotted as result of changing ‘x’, the 
independent variable. 
 
Slope (m), at any point of the line is given by formula 
 
 
m = (y2 – y1)/ (x2 – x1) 
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Correlation coefficient (r) 
 
 
The correlation co-efficient is used as a measure of the correlation between 
two variables. When variables x and y are correlated rather than being functionally 
related. The person correlation co efficient is one of the most convenient method to 
calculate. This is given by 
 
Correlation(r) = [NΣXY - (ΣX) (ΣY) / √ ([NΣX2 - (ΣX)2] [NΣY2 - (ΣY)2])] 
 
where, 
 
N = Number of values or elements 
 
X = First Score 
 
Y = Second Score 
 
ΣXY = Sum of the product of first and Second Scores 
 
ΣX = Sum of First Scores 
 
ΣY = Sum of Second Scores 
 
ΣX2 = Sum of square First Scores 
 
ΣY2 = Sum of square Second Scores 
 
The maximum, value of r is 1. When this occurs, there is exact correlation 
between the two variables. When r is zero, there is complete independence of the 
variables. The minimum value of r is -1. A negative correlation co-efficient indicates 
that the assumed dependence is opposite to what exists and therefore a positive co- 
efficient for the revered relation. The fit must be poor when ‘r’ becomes smaller 
than 0.98 and very poor when less than 0.9. 
 
Standard deviation 
 
 
It is commonly used in statistics as a measure of precision and is more 
meaning full than is the average deviation. It may be thought of as a root mean 
square deviation of values from their average and is expressed mathematically as 
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Where 
 
 
S = Standard deviation 
 
 
If N is large (50 or more) then of course it of immaterial whether the term in the 
denomination is N - 1 or N. 
Σ = sum 
 
 
x        = Mean or arithmetic average. 
 
x - x = Deviation of a value from the mean 
 
N       = Number of observations 
 
Percentage relative standard deviation (% RSD) 
 
It is also known as co efficient of variation. It is defined as the standard 
deviation (S.D) expressed as the percentage of mean. 
 
 
 
R.S.D (%)    = 
 
S.D 
100 
x 
 
 
Where 
 
 
S.D = Standard deviation 
 
 
Variance 
 
The variance is defined as S2  and is more important in statistics than S. 
However, the latter is much more commonly used in chemical data. 
 
Standard error of mean (S.E) 
 
 
The standard error of mean can be defined as the value obtained by the 
division  of  standard  deviation  by  square  root  of  number  of  observations.  It  is 
mathematically expressed as, 
 
 
 
S.E.     = S.D 
n 
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Where, 
 
 
S.D = Standard deviation. 
 
 
n = number of observations. 
 
 
HPLC  METHOD  DEVELOPMENT  (B.K.Sharma,  Instrumental  methods  of 
chemical analysis, 2005) 
 
A good method development strategy should require only as many 
experimental runs as are necessary to achieve the desired final result. Finally method 
development should be as simple as possible and it should allow the use of 
sophisticated tools such as computer modelling. During initial method development, 
a set of initial conditions (detector, column, mobile phase) is selected to obtain the 
first “scouting” chromatograms of the sample. In most cases, these are based on 
reversed-phase separations on a C18 column with UV detection. 
 
SAMPLE AND ANALYTE INFORMATION 
 
This information is useful for the selection of appropriate sample preparation 
procedures as well as the initial detection and chromatographic modes. If critical 
data are not available (e.g., pKa, solubility), separate studies should be initiated as 
soon as possible. The chemical structure of the analyte furnishes data on molecular 
weight  and  the  nature  of  the  functional  groups.  Particular  attention  should  be 
directed  to  acidic,  basic,  aromatic,  or  reactive  functional  groups  from  which 
estimates of pKa, solubility, chromophoric, or stability data can be inferred. 
 
SELECTION OF CHROMATOGRAPHIC MODE 
 
 
Reversed-phase chromatography (RPC), the most common mode for small 
organic molecules. Note that ionisable compounds (acids and bases) are often 
separated by RPC with buffered mobile phases (to keep the analytes in a non- 
ionized state) or with ion-pairing reagents. In reverse phase mode, the mobile phase 
is comparatively more polar than the stationary phase. For the separation of polar or 
moderately polar compounds, the most preferred mode is reverse phase. The nature 
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of the analyte is the primary factor in the selection of the mode of separation .A 
 
second factor is the nature of the matrix 
 
 
SAMPLE PREPARATION 
 
 
Samples occur in various forms 
 
 
        Solutions ready for injection 
 
 
 Solutions  that  require  dilution,  buffering,  addition  of  an  internal 
standard or other volumetric manipulation 
 
        Solids must be dissolved or extracted 
 
 
 Samples that require pre-treatment to remove interferences and/or 
protect the column or equipment from damage. 
 
Most  samples  for  HPLC  analysis  require  weighing  and/or  volumetric 
dilution before injection. Best results are often obtained when the composition of the 
sample solvent is close to that of the mobile phase since this minimizes baseline 
upset and other problems. 
 
Some samples require a partial separation (pre-treatment) prior to HPLC, 
because of need to remove interferences, concentrate sample analytes or eliminate 
“column killers”.      In many cases the development of an adequate sample pre- 
treatment can be challenging for achieving a good HPLC separation. 
 
CHOICE OF THE COLUMN 
 
 
Selection of the column is the first and the most important step in method 
development. Some of the important parameters to be considered while selecting 
chromatographic column 
 
  Length and diameter of the column 
 
  Packing material 
 
  Shape of the particles 
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  Size of the particles 
 
  % of Carbon loading 
 
  Pore volume 
 
  Surface area 
 
  End capping 
 
 
Table No: 1.4 COLUMN SELECTION FLOW CHART 
 
 
Sample Chromatographic mode Column choice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ionisable 
 
(cationic 
 
or anionic) 
 
 
 
Reverse Phase-ion pair (allows 
neutral and charged compounds to 
be simultaneously analyzed) 
 
C18, C8, C6, C4, C2, TMS, CN, 
amino (not for carbonyl 
compounds), phenyl, Hamilton 
PRP-1 (pH 1-13) 
Ion suppression C18, C8, C6, C4, C2, TMS, CN, 
 
amino (not for carbonyl 
compounds), phenyl, Hamilton 
PRP-1 (pH 1-13) 
 
 
 
Anionic Ion Exchange 
 
 
Strong Anion exchange 
Cationic Ion exchange Strong Cation exchange 
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Sample Chromatographic mode Column choice 
 
 
 
Neutral 
 
 
 
Normal phase 
Increasing   polarity   of   bonded 
phases diol 
 
CN < NH2 < Silica < Alumina. 
  
 
 
 
 
 
 
 
 
Reverse phase 
 
 
 
 
 
Increasing  polarity  of  bonding 
phase 
 
C-18 < C-8 < Phenyl  < C-2 < 
TMS 
< CN 
 
 
SELECTION OF SOLVENT DELIVERY SYSTEM 
 
Chromatographic separation with isocratic elution i.e. all constituents of the 
mobile phase is mixed and pumped together as a single solvent, is always preferable 
however, gradient elution is powerful tool in achieving separation between closely 
eluting compounds or compounds having widely differing in polarities. 
 
SELECTION OF MOBILE PHASE 
 
 
The primary objective in selection and optimization of mobile phase is to 
achieve optimum separation of all impurities and degradants from each other and 
from analyte peak. 
In liquid chromatography,  the solute retention is governed by the solute 
distribution factor, which reflects the different interactions of the solute-stationary 
phase,  solute-mobile  phase,  and  mobile  phase-stationary  phase.  For  a  given 
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stationary phase, the nature and the composition of which has to be judiciously 
selected in order to get appropriate and required solute retention. The mobile phase 
has  to  be  adapted  in  terms  of  elution  strength  (solute  retention)  and  solvent 
selectivity (solute separation). Solvent polarity is the key word in chromatographic 
separations since a polar mobile phase will give rise to low solute retention in 
normal phase and high solute retention in reverse phase LC. The selectivity will be 
particularly altered if the buffer pH is close to the pKa of the analytes. The following 
are the parameters, which shall be taken into consideration while selecting and 
optimizing the mobile phase. 
 
    Buffer and its strength 
 
    pH of the buffer or pH of the mobile phase 
 
    Mobile phase composition 
 
 
BUFFERS IF ANY AND ITS STRENGTH 
 
 
Buffer  and  its  strength  play  an  important  role  in  deciding  the  peak 
symmetries and separations. Some of the most commonly employed buffers are 
 
  Phosphate buffers prepared using salts like KH2PO4, K2HPO4, NaH2PO4, 
Na2HPO4 etc. 
 
    Phosphoric acid buffers prepared using H3PO4. 
 
 
    Acetate buffers-Ammonium acetate, Sodium acetate etc. 
 
 
The retention also depends on the molar strengths of the buffer. Molar 
strength is inversely proportional to the retention times. Ideally the strength of the 
buffer shall be opted between 0.01M to 0.2M. After selecting the strength of the 
buffer, it can be varied by about 10 - 20% and the effect of variation was studied 
and it should be rugged for atlseast 2% variation in strength. 
 
pH of the mobile phase 
 
 
It is important to maintain the pH of the mobile phase in the range of 2.0 to 
 
8.0 as most columns does not withstand to the pH which are outside this range. This 
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is due to the fact that the silioxane linkages are cleaved below pH 2.0, while pH 
 
values above 8.0 the silica may dissolve. 
 
 
pHof the buffer 
 
 
pH plays an important role as it controls the elution properties by controlling 
the ionization characteristics. In RP-HPLC the retention of analytes is related to 
their hydrophobicity. The more hydrophobic the analyte, the longer it is retained. So, 
acid shows decrease in retention with increasing pH while base show increase in 
retention. 
 
Figure no 1.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SELECTION OF BUFFER 
 
 
Optimum buffering capacity occurs at a pH equal to the pKa of the buffer. 
Almost all of the pH related change in retention occurs for pH values within ±1.5 
units of pKa value. Out side this range the compound is either ionized or unionized, 
and its retention doesn’t change much with pH. 
 
The relationship between RP-HPLC retention and mobile phase pH is more 
complicated for compounds that contain multiple acidic and/or basic groups. Buffer 
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strength of 10-50 mM are generally adequate. The buffers showing UV absorbance 
below 220 nm were preferable. 
 
Table No: 1.5 COMMONLY USED BUFFERS FOR RP-HPLC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SELECTION OF FLOW RATE 
 
 
Generally flow rate shall not be more than 2.0 ml/min. The flow rate shall be 
selected based on the following data. 
 
    Retention time 
 
 
    Column back pressure 
 
 
    Resolution between the peaks 
 
 
    Peak symmetries 
 
 
The flow rate which gives least retention times, good peak symmetries, least 
back pressures and better separation will be selected. 
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Development of HPLC method 
 
 
 
Information on sample, define the separation 
goal 
 
 
 
 
 
Need for special HPLC procedure, Sample 
pretreatment etc 
 
 
 
Choose detector and detector settings 
 
 
 
 
 
 
Choose LC condition  preliminary run for 
estimation best separation condition. 
 
 
 
 
Optimize separation condition 
 
 
 
 
 
 
Check for problem or requirement for the 
special procedure 
 
 
 
 
 
 
Quantitative method                                    Qualitative method 
 
 
 
 
 
Validate the method for transferring to Lab 
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PERFORMANCECALCULATIONS 
SYSTEM SUITABILITY PARAMETERS 
1)  Retention time (tR) 
 
2)  Resolution (RS) 
 
3)  Capacity factor (k`) 
 
4)  Selectivity (α) 
 
5)  Number of Theoretical plates (N) 
 
6)  HETP 
 
7)  Asymmetry factor 
 
8)  Tailing factor 
 
1) Retention time 
 
 
Chromatographic retention is to measure the time between the injection point 
and maximum of the detector response for correspondent compound. This parameter 
called “retention time” is inversely proportional to the eluent flow rate. 
 
2) Resolution 
 
The goal of most HPLC analyses is the separation of one or more analytes in 
the sample from all other components present. Resolution (Rs) is a measure of the 
degree of separation of two adjacent analytes. Resolution of two adjacent band is 
defined as the distance between band peaks divided by the average band width. 
Retention and band width are measured in units of time. 
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Where, 
 
 
Rt1 and Rt2 are the retention times of components 1 and 2 
 
 
W1 and W2 are peak widths of components 1 and 2. 
 
 
RS ≥ 2.0 is a desirable target for method development. 
 
3) Capacity factor (K’) 
 
 
It is a measure of a sample peak in the chromatogram being specific for a 
given compound, a parameter which specifies of a substance to be separated. 
 
 
 
 
The retention factor k is given by the equation 
 
k= (tR – t0  ) / t0 
 
Where, 
 
‘tR’ is the band retention time 
 
‘t0’ is the column dead time. 
 
 
 
 
4) Selectivity (α) 
 
 
The selectivity α is a measure of relative retention of two components in a 
mixture.  The  ideal  value  of  selectivity  is  2.  It  can  be  calculated  by  using  the 
following formula. 
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  
V2   V0   
V1   V0 
 
 
Where, V0 is the void volume of the column and V2 and V1 are the retention 
volumes of the second and the first peak, respectively. 
 
 
 
 
COLUMN EFFICIENCY & PLATE NUMBER 
 
 
The number of theoretical plates or plate number is a measure of column 
efficiency. An efficient column produces sharp peaks and can separate many sample 
components in a relatively short time. Theoretical plates (N) are defined as the 
square of the ratio of the retention time divided by the standard deviation of the peak 
(σ). 
 
 
 
 
Another way to express efficiency of column is by calculating height 
equivalents of theoretical plates (HETP). 
 
H = L/N 
Where H = HETP; L = Length of the column; N = number of theoretical plates. 
Lower the HETP, higher is the efficiency of the column, i.e., higher the theoretical 
plates more efficient the column. 
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7) Peak asymmetry 
 
Peak asymmetry factor as can be used as a criterion of column performance. 
The peak half width, divided by the corresponding front half width, a gives the 
asymmetry factor. 
 
 
A   
 b 
s        a 
 
 
Where, 
 
‘b’, is the distance at 50% peak height between leading edge to the perpendicular 
drawn from the peak maxima 
 
‘a’, is the width of the peak at half the peak height. 
 
8) Tailing factor 
 
 
The tailing factor T, a measure of peak symmetry, is unity for perfectly 
symmetrical peaks and its value increases as tailing becomes more pronounced. 
 
In some cases, values less than unity may be observed. As peak asymmetry 
increases, integration, hence precision becomes less reliable. 
 
According to USP (2000) Peak-tailing factor can be calculated by using the 
formula 
 
T = W0.05/2 f 
 
 
Where, 
 
 
‘W0.05’ is the width of the peak at 5% height and 
 
 
‘f’ is the distance from the peak maximum to the leading edge of the peak, 
the distance being measured at a point 50% of the peak height from the base line. 
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Table No: 1.6 System Suitability Parameters specifications 
 
S. No. Parameter Specifications 
1 Capacity Factor (k’) o.5 < k < 20 
2 Theoretical Plates >2000 
3 Tailing factor <2 
4 Resolution >2 
5 Selectivity >2 
 
 
ANALYTICAL METHOD VALIDATION 
 
Method validation can be defined as per ICH as, “Establishing documented 
evidence, which provides a high degree of assurance that a specific activity will 
consistently produce a desired result or product meeting its predetermined 
specifications and quality characteristics”. 
 
SPECIFICITY/SELECTIVITY 
 
 
The terms selectivity and specificity are often used interchangeably. 
According to ICH, the term specific generally refers to a method that produces 
distinguishable responses for a single analyse of number of chemical entities that 
may or may not be distinguished from each other. If the response is distinguished 
from all other responses, the method is said to be selective. 
 
LINEARITY 
 
Linearity of an analytical procedure is its ability (with in a given range) to 
obtain test results which are directly proportional the concentration (amount) of 
analyte in the sample. It may be demonstrated directly on the drug substance (by 
dilution of a standard stock solution) and/or separate weighing of synthetic mixtures 
of the drug product components, using the proposed procedure. Linearity should be 
evaluated by visual inspection of a plot of signals as a function of analyte 
concentration or content. If there is a linear relationship, test results should be 
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evaluated  by  appropriate  statistical  methods,  for  example,  by  calculation  of  a 
regression line by the method of least squares. 
 
RANGE 
 
Range is  the interval  between  the upper and  lower concentration  of the 
analyte in the sample for which it has a suitable level of precision, accuracy and 
linearity. 
 
ACCURACY 
 
Accuracy is the measure of the closeness of the experimental value to that of 
the true value. Accuracy should be established across the specified range of the 
analytical procedure. 
 
A. Assay 
 
 
1.1 Drug Substance 
 
 
Several methods of determining accuracy are available 
 
 
a)  Application  of  an  analytical  procedure  to  an  analyte  of  known  purity  (e.g. 
reference material) 
 
b) Comparison of the results of the proposed analytical procedure with those of a 
second well-characterized procedure, the accuracy of which is stated and/or defined. 
 
c) Accuracy may be inferred once precision, linearity and specificity have been 
established. 
 
1.2. Drug Product 
 
 
Several methods for determining accuracy are available 
 
 
a) Application of the analytical procedure to synthetic mixtures of the drug product 
components to which known quantities of the drug substance to be analysed have 
been added. 
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b) In cases where it is impossible to obtain samples of all drug product components, 
it may be acceptable either to add known quantities of the analyte to the drug 
product or to compare the results obtained from a second, well characterized 
procedure, the accuracy of which is stated and/or defined. 
 
c) Accuracy may be inferred once precision, linearity and specificity have been 
established. 
 
2. Impurities (Quantitation) 
 
 
Accuracy should be assessed on samples (drug substance/drug product) 
spiked with known amounts of impurities. In cases where it is impossible to obtain 
samples  of  certain  impurities  and/or  degradation  products,  it  is  considered 
acceptable to compare results obtained by an independent procedure. The response 
factor of the drug substance can be used. It should be clear how the individual or 
total impurities are to be determined e.g., weight/weight or area percent, in all cases 
with respect to the major analyte. Accuracy should be assessed using a minimum of 
9 determinations over a minimum of 3 concentration levels covering the specified 
range (e.g. 3 concentrations /3 replicates each of the total analytical procedure). 
Accuracy should be reported as percent recovery by the assay of known added 
amount of analyte in the sample or as the difference between the mean and the 
accepted true value together with the confidence intervals. 
 
PRECISION 
 
Precision is the measure of how close the data values are to each other for a 
series of measurements under the same analytical conditions obtained from multiple 
sampling of the same homogeneous sample. Precision may be considered at three 
levels. 
 
A. Repeatability 
 
1. Injection Repeatability 
 
The sensitivity or precision as measured by multiple injections of a 
homogeneous sample (prepared solution) indicates the performance of the HPLC 
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instrument under the chromatographic conditions and day tested. The specification, 
as the coefficient of variation in % or relative standard deviation (RSD), set here 
will determine the variation limit of the analysis. The tighter the value, the more 
precise or sensitive to variation one can expect the results. This assumes that the 
chromatograph does not malfunction after the system suitability testing has been 
performed. The set of four duplicate samples were injected sequentially. Variations 
in peak area and drift of retention times are noted. 
 
Recommendations 
 
As part of methods validation, a minimum of 10 injections with an RSD of 2% 
is recommended. With the methods for release and stability studies, an RSD of 2% 
for precision of the system suitability tests for at least five injections (n=5) for the 
active drug either in drug substance or drug product is desirable. For low-level 
impurities, higher variations may be acceptable. 
 
2. Analysis Repeatability 
 
Determination, expressed as the RSD, consists of multiple measurements of a 
sample by the same analyst under the same analytical conditions. For practical 
purpose, it is often combined with accuracy and carried out as a single study. 
 
B. Intermediate precision 
 
Intermediate precision was previously known as part of ruggedness. The 
attribute evaluates the reliability of the method in a different environment other than 
that used during development of the method. The objective is to ensure that the 
method will provide the same results when similar samples are analyzed once the 
method development phase is over. Depending on time and resources, the method can 
be tested on multiple days, analysts, instruments, etc. 
 
C. Reproducibility 
 
As   defined   by   ICH,   reproducibility   expresses   the   precision   between 
laboratories as in collaborative studies. Multiple laboratories are desirable but not 
always attainable because of the size of the firm. 
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LIMIT OF DETECTION 
 
Limit of detection is the lowest concentration of analyte in a sample which can 
be detected, but not necessarily quantitated, as  an exact value under the stated 
experimental conditions. 
 
A. Based on Visual Evaluation 
 
Visual evaluation may be used for non-instrumental methods but may also be 
used with instrumental methods. The detection limit is determined by the analysis of 
samples with known concentrations of analyte and by establishing the minimum 
level at which the analyte can be reliably detected. 
 
B. Based on Signal-to-Noise 
 
This approach can only be applied to analytical procedures  which exhibit 
baseline noise. Determination of the signal-to-noise ratio is performed by comparing 
measured signals from samples with known low concentrations of analyte with those 
of blank samples and establishing the minimum concentration at which the analyte 
can be reliably detected. A signal-to-noise ratio between 3 or 2:1 is generally 
considered acceptable for estimating the detection limit. 
 
C. Based on the Standard Deviation of the Response and the Slope 
 
The detection limit (DL) may be expressed as 
 
 
 
Where, 
 
σ = the standard deviation of the response 
 
S = the slope of the calibration curve 
 
LIMIT OF QUANTIFICATION 
 
Limit of quantification is the lowest concentration of analyte in a sample 
which  can  be  quantitatively determined  with  acceptable  precision  and  accuracy 
under the stated experimental conditions. Several approaches for determining the 
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quantification limit are possible, depending on whether the procedure is a non- 
instrumental or instrumental.  Approaches  other  than  those listed  below may be 
acceptable. 
 
A. Based on Visual Evaluation 
 
Visual evaluation may be used for non-instrumental methods but may also be 
used with instrumental methods. The quantification limit is generally determined by 
the analysis of samples with known concentrations of analyte and by establishing the 
minimum level at which the analyte can be quantified with acceptable accuracy and 
precision. 
 
B. Based on Signal-to-Noise Approach 
 
This  approach  can  only  be  applied  to  analytical  procedures  that  exhibit 
baseline noise. Determination of the signal-to-noise ratio is performed by comparing 
measured signals from samples with known low concentrations of analyte with those 
of blank samples and by establishing the minimum concentration at which the analyte 
can be reliably quantified. A typical signal-to-noise ratio is 10:1. 
 
C. Based on the Standard Deviation of the Response and the Slope 
 
The quantification limit (QL) may be expressed as 
 
 
 
Where, 
 
σ = the standard deviation of the response 
 
S = the slope of the calibration curve 
 
The slope S may be estimated from the calibration curve of the analyte. 
 
RUGGEDNESS 
 
Ruggedness is the degree of reproducibility of results obtained under a variety 
of  conditions,  such  as  different  laboratories,  analysts,  instruments,  environmental 
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conditions, operators and materials. Ruggedness is determined by the analysis of 
aliquots from homogeneous lots in different laboratories. 
 
ROBUSTNESS 
 
Robustness as a measure of the method's capability to remain unaffected by 
small, but deliberate variations in method parameters and provides an indication of its 
reliability during normal usage. Robustness can be partly assured with good system 
suitability specifications. The evaluation of robustness should be considered during 
the development phase and depends on the type of procedure under study. 
 
Examples of typical variations are 
 
 
 Stability of analytical solutions 
 
 Extraction time 
 
  Influence of variations of pH in a mobile phase 
 
  Influence of variations in mobile phase composition 
 
  Different columns (different lots and/or suppliers) 
 
  Temperature 
 
  Flow rate. 
 
  Different columns (different lots and/or suppliers) 
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2. LITERATURE REVIEW 
 
 
1. Nayak, Diptish Ku, Kumar, VankarKaushik, Patnaik, Arabinda, Vol.4, 
No.4, pp 1595-1600, Oct-Dec 2012 . “Simultaneous estimation of 
Rabeprazole sodium and diclofenac sodium by RP-HPLC method in 
combined dosage-form”, International Journal of Pharm Tech 
Research,2(2):1488 . The solvent used is pH 6.8 phosphate buffer. Linearity 
range was 2-10µg/ml and 5-25 µg/ml for Rabeprazole sodium and 
Diclofenac sodium respectively. The methods were validated with respect to 
linearity, precision and accuracy. 
2. P.Palanisamy, B.Jayakar, M.Kumar, R.Margret Chandra, 
B.S.Venkateshwralu Development Of A Rp   Hplc  Method For The 
Estimation Of Diclofenac Sodium, Vitamin B, Vitamin B6 and Vitamin B12  
Insoft Gelatin Capsule Dosage Form. IJPTP, 2014, 5(3),1002-1013.The 
Diclofenac Sodium, the separation was  carried out in Phenomenex ODS C 
18 column (150 x 4.6mm;  5µm) using mobile phase consisting of mixture 
of  400mL potassium hydrogen phosphate (pH 3.0) and 600mL of 
Acetonitrile. The flow rate was 1.0mL/min and effluent was detected at 
254nm. The retention time of Diclofenac sodium was 5.4 min. The 
percentage recovery was within the range between 100.00% and 101.86% 
for Diclofenac Sodium. The linearity range was found to be 20-400µg/mL 
(r2=1) for Diclofenac Sodium.  
3. B.Gowramma*, S. Rajan, S. Muralidharan, S. N. Meyyanathan and B. 
Suresh. “  A Validated RP-HPLC Method For Simultaneous Estimation Of 
Paracetamol And Diclofenac Potassium In Pharmaceutical Formulation” . 
Vol.2, No.1, pp 676-680, Jan-Mar 2010 . The method was carried out on a 
Phenomenex LUNA C18 (25 cm x 4.6 mm i.d., 5 µ) column with a mobile 
phase consisting of acetonitrile: sodium dihydrogen ortho phosphate 
(adjusted to pH 3.5 using orthophosphoric acid) in the ratio of 70:30 v/v at a 
flow rate of 1.0 mL/min. Detection was carried out at 278 nm. Aceclofenac 
was used as an internal standard. The retention times of paracetamol, 
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diclofenac potassium and aceclofenac were 5.9, 9.4 and 3.12 min, 
respectively. The developed method was validated in terms of accuracy, 
precision, linearity, limit of detection, limit of quantitation and solution 
stability. The proposed method can be used for the estimation of these drugs 
in combined dosage forms. 
4. Terasa Kubala, Baldev Gambhir & S. Ian Borst.  A Specific Stability 
Indicating Hplc Method to Determine Diclofenac Sodium in Raw Materials 
and Pharmaceutical Solid Dosage Forms .Pages 749-757 | Published online: 
20 Oct 2008 . This method is specific, accurate and stability indicating. The 
method employs a reverse-phase octylsilane (C18) column with a mobile 
phase composed of acetonitrile/methanol/pic B-6 (25:25:50) and detection at 
229 nm. The method resolves six principal related compounds with 
quantitation in the range 0.3-1.5%. Assay recoveries by spiking commercial 
formulations with diclofenac sodium were 99.64 ± 1.30%. Drug content in 
several commercial formulations are reported. Accelerated stability tests 
were conducted on raw materials and drug products and 1-(2,6-
dichlorophenyl)-2-indolin-2-one was identified for the first time as a 
degradation product in solid dosage forms which are stressed under 
humidity and heat. 
5. Satish, A.,Patel.,Kalpesh, M., Prajapati, “Development and Validation of 
RP-HPLC method for simultaneous Estimation of Chlorozoxazone and 
Diclofenacsodium combination”,pharma tutor -1715. The chromatographic 
separation was performed on ACE 5 C18 column (150 mm × 4.6 mm i.d., 5 
µm particle size). Mobile phase consisted of a mixture of phosphate buffer 
(0.02 M KH2PO4, pH adjusted to 3 using orthophosphoric acid), acetonitrile 
and methanol (30: 30: 40, v/v/v) at a flow rate of 1.0 ml/min. The detection 
wavelength was set at 279 nm. The proposed method was validated for 
linearity, accuracy, precision, LOD and LOQ. The calibration curve was 
linear over the range of 2-50 µg/ml for Chlorzoxazone and 2-50 µg/ml for 
Diclofenac sodium. The retention times were 2.8 min for Chlorzoxazone 
and 6.3 min for Diclofenac sodium. The mean recoveries were 101.1 ± 0.47 
and 100.8 ± 0.77 for Chlorzoxazone and Diclofenac sodium, respectively. 
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The method has been successfully applied to determine the content of both 
drugs from the synthetic mixture. Hence, the method can be easily adopted 
for quality control analysis of both drugs in mixture. 
 
6. Venkata Raveendra Babu Vemula, Pankaj Kumar Sharma, Asian J Pharm 
Clin Res, Vol 6, Suppl 3, 2013, 186-189. RP-HPLC Method Development 
And Validation For Simultaneous Estimation Of Diclofenac And 
Tolperisone In Tablet Dosage Form.  Chromatography was carried out 
isocratically at 30°C ± 0.5°C on an XDB C-18 column (4.6 x 150mm, 5µ 
particle size) with a mobile phase composed of acetonitrile -phosphate 
buffer pH-3.4 (30:70% v/v) at a flow rate of 1.0 mL/min. Detection was 
carried out using a PDA detector at 260 nm. 
7. Modi, M.V., M.M. Patel, Patel, C.N., Bharadia, P.D., “Development and 
validation of new RP-HPLC method for the estimation of Diclofenac 
Sodium and Famotidine in bulk and pharmaceutical dosage form”, Inventi 
impact: pharm Analysis and Quality Assurance, 2011,11:154. 
Chromatography was performed on a Varian C18 column (250 mm x 4.6 
mm i.d., 5 µm particle size), column with mobile phase containing 
acetonitrile,methanol and water in the ratio of 25:30:45 v/v.The flow rate 
was 1.0 ml/min and the eluent was monitored at 283 nm. The selected 
chromatographic conditions were found to effectively separate Diclofenac 
sodium (RT- 2.432 min) and Famotidine (RT- 5.082 min). Linearity for 
Diclofenac sodium and Famotidine were found in the range of 5-35µg/ml 
and 2-14µg/ml. The values obtained of LODs were 0.036µg/ml and 
0.028µg/ml, LOQs were 0.11µg/ml and 0.088µg/ml for Diclofenac sodium 
and Famotidine, respectively. The proposed method was found to be fast, 
accurate, precise, reproducible and rugged and can be used for simultaneous 
analysis of Diclofenac sodium and Famotidine in combined pharmaceutical 
formulations. 
8. Indian pharmacopoeia (2010), The Indian pharmacopoeia 
Commission, Ghaziabad. 
9. United State Pharmacopoeia 30- NF 25, 2007. 
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International Conference of Harmonization, Geneva: 1996.  
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ed. Merck Research Laboratories, Division of Whitehouse Station, NJ: 
Merck and Co. Inc; 2001. 
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3. OBJECTIVE AND PLAN OFWORK 
 
 
 
The drug analysis plays an important role in all aspects regarding the drug 
right the development to the therapeutic use of the drug. Industries manufacturing 
pharmaceutical must ensure that the raw material used and the final product obtained 
meets the required specification to fulfill this purpose they rely upon quantitative 
chemical analysis. 
The Literature survey indicates that a very few methods were developed for 
the estimation of Diclofenac Sodium   by RP-HPLC. So an attempt was made to 
develop a new RP-HPLC method which is more reliable, economical and flexible. 
 
The objective of the present work is to develop a new method of estimation 
for Diclofenac Sodium in all formulations. So an attempt was made to develop and 
validate a simple, precise, accurate, linear and rapid  RP-HPLC method as per ICH 
guidelines for the estimation of  Diclofenac Sodium in pure pharmaceutical dosage 
forms and to apply the developed method to determine the validation of compounds. 
 
Plan of Work 
 
 To obtain thorough knowledge of Practical RP-HPLC method. 
 
 To establish the initial chromatographic conditions for  method 
development of  assay for Diclofenac Sodium . 
 To  validate  the  developed  method  a  per  the  Q2  specifications  of  
ICH guidelines 
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4. DRUG PROFILE 
 
 
Name                                                :    Diclofenac Sodium    
 
 
 
Chemical structure 
 
 
 
       Chemical Formula                            :    C14H10Cl2NNaO2  
 
IUPAC name                                   :    Sodium 2-[(2,6-dichlorophenyl)-amino] 
phenylacetate. 
 
 
       Molecular weight                              :    318.1 
  
 
Description                                       :    White to off-white, hygroscopic, crystalline 
powder.  
Solubility                                          :    Freely soluble in methanol; soluble in ethanol; 
sparingly soluble in water; practically insoluble 
in chloroform and in ether.  
 
Melting point                                      :    About 280ºC  
 
Drug category                                   :    Cyclo-oxygenase inhibitor; analgesic; anti-
inflammatory 
 
Mechanism of action 
 
The primary mechanism responsible for its anti-inflammatory, antipyretic, 
and analgesic action is thought to be inhibition of prostaglandin synthesis by 
inhibition of cyclooxygenase (COX). It also appears to exhibit bacteriostatic activity 
by inhibiting bacterial DNA synthesis.  
Inhibition of COX also decreases prostaglandins in the epithelium of the 
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stomach, making it more sensitive to corrosion by gastric acid. This is also the main 
side effect of diclofenac. Diclofenac has a low to moderate preference to block the 
COX2-isoenzyme (approximately 10-fold) and is said to have, therefore, a somewhat 
lower incidence of gastrointestinal complaints than noted 
with indomethacin and aspirin.  
 
 
Pharmacokinetics 
 
 
Bioavailability                                  :   Approximately 50% bioavailability orally. 
 
 
Metabolism                                       :    Hepatic, oxidative, primarily by CYP2C9, also 
by CYP2C8, CYP3A4, as well as conjugative 
by glucuronidation (UGT2B7)and sulfation; no 
active metabolites exist 
 
Half life                                             :   1.2-2.0 hours (35% of the drug enters 
enterohepatic recirculation) 
 
 
Excretion                                          :   40% biliary 60% urine  
 Dosage form                                     :   Capsule             
Route                                                 :   oral               
Medical uses 
Diclofenac is used to treat pain, inflammatory disorders, and dysmenorrhea 
      Adverse effects 
 
Indigestion, gas, stomach pain, nausea, vomiting; diarrhea, constipation; 
headache, dizziness, drowsiness; stuffy nose; itching, increased sweating; increased 
blood pressure; or. swelling or pain in your arms or legs. 
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  5. MATERIALS AND INSTRUMENTS USED 
 
 
 
 
Instrumentation 
 
a) System: HPLC  Aglilent  -1260 series 
b) Detector: PDA   
c) Injector: Autosampler 
d) Column: C18, 15 cm X 4.6 mm, 5 µm 
e) Henna pH meter 
f) Gelman sicence vaccum pump 
g) Ultra sonicator 
h) Millipore – solvent filtration unit 
i) Shimadzu electronic balance 
 
 
 
The  HPLC  system  used  comprised  of  degasser,  quarternary  pump,  
auto sampler, thermostated column compartment, photo diode array detector. 
 
 
Chemicals and Reagents used 
 
 Milli Q Water: HPLC grade, supplied by Thomas baker 
chemicals Ltd., Mumbai, India. 
  
 Potassium dihydrogen orthophosphate: AR grade, Supplied by 
Qualigens  Fine Chemicals  Ltd., Mumbai, India. 
 
 Acetonitrile: HPLC grade, Supplied by Spectrochem, Mumbai, 
India. 
 Orthophosphoric acid: AR grade, Supplied by Qualigens  Fine 
Chemicals  Ltd., Mumbai, India. 
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Information regarding Drug sample 
 
 
Dosage form of sample                                : Soft gelatin Capsule 
 
 
No. of Drugs in combination                        : 1 
 
 
Label claim  
Diclofenac  Sodium BP : 50 mg  
Solubility                                                    : Freely soluble in methanol & 
Acetonitrile; soluble in ethanol; sparingly 
soluble in water; practically insoluble in 
chloroform and in ether. 
 
 
Manufactured by                                           : Caplin point laboratories ltd  
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 6.  METHOD DEVELOPMENT AND OPTIMIZATION 
 
 
SOLUBILITY 
 
According to literature review collected Diclofenac Sodium   are freely 
soluble in methanol & Acetonitrile; soluble in ethanol; sparingly soluble in water; 
practically insoluble in chloroform and in ether. The solubility of there  drugs  in  
Acetonitrile   and  water  was  checked.  Finally,  The mixture of Acetonitrile and 
B u f f e r  ( 6.8 g of Potassium dihydrogen orthophosphate in 1000 mL of water and 
then adjust the pH to 3.00 with dilute Orthophosphoric acid. ) in the ratio of  60:40 
v/v   was chosen for present work. 
 
SELECTION OF CHROMATOGRAPHIC METHOD FOR SEPARATION 
 
 
Selection of the method depends upon the nature of sample 
(ionic/ionisable/neutral), its molecular weight and solubility. Most of the drugs are 
polar in nature and hence reversed phase HPLC is preferred over the normal phase 
HPLC method. The drug combinations concerned for the present study are also 
polar. Hence reversed phase HPLC was selected for separation of the drug 
combination because of its suitability. 
 
SELECTION OF DETECTION OF WAVELENGTH (λ max )  
 
Selection  of  detection  of  wavelength  is  a  critical  step  in  the  analytical 
method.  The spectrum of diluted solutions was scanned over the range of 200 – 400 
nm in spectrum mode.  
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UV SPECTRA OF DICLOFENAC SODIUM    
  
 
Identification by IR Spectroscopy 
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OPTIMIZED CHROMATOGRAPHIC CONDITIONS FOR ASSAY  
 
Column                : Inertsil ODS-3 C18, 25 cm x 4.6 mm, 5 µm  
Flow Rate                            : 1.0 mL/minute 
Pump mode      : Isocratic  
Detector wavelength               : 254 nm 
Injection volume              : 20 µL 
Column Temperature            : 25.0˚C 
Mobile phase composition: Acetonitrile and Buffer (6.8 g of Potassium dihydrogen 
orthophosphate in 1000 mL of water and then adjust the pH to 3.00 with dilute 
Orthophosphoric acid) in the ratio of  60:40 v/v.    
 
Diluent:  Mobile phase 
Prepare a mixture Acetonitrile and Buffer (6.8 g of Potassium dihydrogen 
orthophosphate in 1000 mL of water and then adjust the pH to 3.00 with dilute 
Orthophosphoric acid. ) in the ratio of  60:40 v/v.   , mix well. Filter the solution 
through 0.45 µm nylon filter and sonicate for 10 minutes 
 
 
 
 
Methodology adopted 
 
 
 Mobile phase selection 
 
 Preparation of buffer solution 
 
 Preparation of mobile phase 
 
 Preparation of diluent 
 
 Preparation of standard stock solution 
 
 Preparation of standard solution 
 
 Preparation of sample solution 
 
 Setting the instrumental parameters before performing the analysis for 
 
1.   Detector 
 
2.   Pump 
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 Development of chromatogram and determination of retention time. 
 
PREPARATION OF SOLUTIONS 
Preparation of buffer solution 
Weigh and dissolve 6.8 g of Potassium dihydrogen orthophosphate in 1000 
mL of water and then adjust the pH to 3.00 with dilute Orthophosphoric acid.  
 
Selection of mobile phase 
 
 
The mobile phase system consisting of Acetonitrile and Buffer (6.8 g of 
Potassium dihydrogen orthophosphate in 1000 mL of water and then adjust the pH to 
3.00 with dilute Orthophosphoric acid. ) in the ratio of  60:40 v/v was found to be 
effective in the separation of Diclofenac Sodium in pure form as well as in dosage 
forms. 
 
Preparation of Mobile Phase 
 
Prepare a mixture 400 volume of Buffer and 600 volume of Acetonitrile, mix 
well. Filter the solution through 0.45 µm nylon filter and sonicate for 10 minutes. 
 
 
 
 
Preparation of Diluent 
 
Prepare a mixture 400 volume of Buffer (6.8 g of Potassium dihydrogen 
orthophosphate in 1000 mL of water and then adjust the pH to 3.00 with dilute 
Orthophosphoric acid. )  and 600 volume of Acetonitrile, mix well. Filter the solution 
through 0.45 µm nylon filter and sonicate for 10 minutes. 
 
 [Note: Perform the tests in the dark or under golden fluorescent or other low-actinic 
light and use low actinic glassware’s in the performance of the following procedure.] 
Procedure for preparation of analytical solution: 
Preparation of standard solution (50.0 mcg/mL of Diclofenac Sodium): 
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Weigh accurately about 50 mg of Diclofenac Sodium working standard and transfer 
into 50 mL volumetric flask, add 30 mL of diluent and sonicate for 5 minutes to 
dissolve. Cool and dilute up to the volume with diluent and mix well. Transfer 5 mL of 
the above solution through pipette into 100 mL volumetric flask and dilute up to the 
volume with diluent. Mix and filter the solution through 0.45 µm nylon filter and 
collect the solution in HPLC vial after discarding about first 2 mL of the filtrate. 
Preparation of sample solution (50.0 mcg/mL of Diclofenac Sodium): 
Accurately weigh and transfer 5 capsules (equivalent to 250 mg of Diclofenac 
Sodium) into 250 mL volumetric flask. Add about 25 mL of water and sonicate for 20 
minutes to disperse the capsules shell. Add about 120 mL of diluent and sonicate for 
20 minutes to dissolve. Cool and dilute up to the volume with diluent and mix well. 
Transfer 5 mL of the above solution through pipette into 100 mL volumetric flask and 
dilute up to the volume with diluent. Mix and filter the solution through 0.45 µm nylon 
filter and collect the solution in HPLC vial after discarding about first 2 mL of the 
filtrate. 
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7. METHOD VALIDATION 
 
 
Validation of analytical method is a process to establish that the performance 
characteristics of the developed method meet the requirement of the intended 
analytical application. (Lloyd R. Synder, 1997) (ICH Harmonized Tripartite 
Guidelines, 2005) 
 
SYSTEM SUITABILITY PARAMETERS 
 
 
System suitability is the test to ensure that the methods can generate results 
of acceptable accuracy and precision. (Lloyd R. Synder, 1997) 
 
Standard solutions of Diclofenac Sodium  were prepared as per test method 
and five replicate injections were made to study system suitability parameters. 
 
Parameters studied 
Tailing Factor. 
Number of theoretical plates (N). 
Retention time. 
Relative standard deviation . 
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Typical analytical parameters used in method validation include 
 
 
1.   Specificity 
 
 
2.   Linearity and Range 
 
 
3.   Precision 
 
 
4.   Accuracy 
 
 
5.   Ruggedness 
 
 
6.   Limit of detection 
 
 
7.   Limit of quantitation 
 
 
8.   Selectivity 
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SPECIFICITY 
 
 
The  specificity of  the  method  can  be  defined  as  the  ability to  measure 
accurately the concentration of an analyte in the presence of all other sample 
materials. (Lloyd R. Synder, 1997) (ICH Harmonized Tripartite Guidelines, 2005) 
 
Procedure: 
Inject the blank, placebo, standard and sample preparations based on “Injection 
sequence” detailed below and measure the corresponding area. 
Injection sequence  
Table No:7.1 
 
Particulars Number of Injection 
Blank  1 
Placebo preparation 1 
Standard preparation 5 
Sample preparation 2 
Bracketing standard 1 
 
Acceptance criteria: 
 No any peak should be obtained in the retention time of Diclofenac Sodium  from the 
blank and placebo chromatograms. 
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System suitability results: 
Table No:7.2 
S.No. Parameter 
Results 
obtained 
Acceptance criteria 
01 Tailing factor  1.30 NMT 2.0 
02 Theoretical Plates  8494 NLT 2000 
03 % RSD  0.068 NMT 2.0 % 
 
Specificity Results: 
Table No:7.3 
S.No. Name of the 
solution 
Results obtained Acceptance criteria 
01 Blank 
No  peak  found in the 
retention time of Diclofenac 
Sodium    
No any peak should be 
found in the retention 
time of Diclofenac 
Sodium    
02 Placebo 
No  peak  found in the 
retention time of Diclofenac 
Sodium    
No any peak should be 
found in the retention 
time of Diclofenac 
Sodium    
 
 
LINEARITY AND RANGE 
 
 
Linearity is  the  measure  of  how  well  a  calibration  plot  of  response  Vs 
concentration approximates a straight line. Linearity can be assessed by 
performing the single measurement s at several analyte concentrations. The data 
are then processed using a linear least square regression. The resulting plot slope, 
intercept and correlation coefficient provide the desired information on linearity. 
(Lloyd R. Synder, 1997). (ICH Harmonized Tripartite Guidelines, 2005). 
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Ability to obtain test results which are directly proportional to the concentration of 
analyte. For an establishment of the linearity 60%, 80%, 100%, 120%, and 160% of 
standard and sample concentrations shall be used. 
Preparation of Linearity from standard: 
Standard stock solution (1000 mcg/mL of Diclofenac Sodium): 
Weigh accurately about 50 mg of Diclofenac Sodium working standard and transfer 
into 50 mL volumetric flask, add 30 mL of diluent and sonicate for 5 minutes to 
dissolve. Cool and dilute up to the volume with diluent and mix well.  
60 % Linearity standard concentration (30.0 mcg/mL of Diclofenac Sodium): 
Transfer 3.0 mL of above standard stock solution through pipette into 100 mL 
volumetric flask. Dilute up to the volume with diluent. Mix and filter the solution 
through 0.45 µm nylon filter and collect the solution in HPLC vial after discarding 
about first 2 mL of the filtrate. 
80 % Linearity standard concentration (40.0 mcg/mL of Diclofenac Sodium): 
Transfer 4.0 mL of above standard stock solution through pipette into 100 mL 
volumetric flask. Dilute up to the volume with diluent. Mix and filter the solution 
through 0.45 µm nylon filter and collect the solution in HPLC vial after discarding 
about first 2 mL of the filtrate. 
100 % Linearity standard concentration (50.0 mcg/mL of Diclofenac Sodium):  
Transfer 5.0 mL of above standard stock solution through pipette into 100 mL 
volumetric flask. Dilute up to the volume with diluent. Mix and filter the solution 
through 0.45 µm nylon filter and collect the solution in HPLC vial after discarding 
about first 2 mL of the filtrate. 
120 % Linearity standard concentration (60.0 mcg/mL of Diclofenac Sodium): 
Transfer 6.0 mL of above standard stock solution through pipette into 100 mL 
volumetric flask. Dilute up to the volume with diluent. Mix and filter the solution 
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through 0.45 µm nylon filter and collect the solution in HPLC vial after discarding 
about first 2 mL of the filtrate. 
160 % Linearity standard concentration (80.0 mcg/mL of Diclofenac Sodium): 
Transfer 8.0 mL of above standard stock solution through pipette into 100 mL 
volumetric flask. Dilute up to the volume with diluent. Mix and filter the solution 
through 0.45 µm nylon filter and collect the solution in HPLC vial after discarding 
about first 2 mL of the filtrate. 
Preparation of Linearity solution from Sample: 
Sample stock solution (1000 mcg/mL of Diclofenac Sodium): 
Accurately weigh and transfer 5 capsules (equivalent to 250 mg of Diclofenac 
Sodium) into 250 mL volumetric flask. Add about 25 mL of water and sonicate for 20 
minutes to disperse the capsules shell. Add about 120 mL of diluent and sonicate for 
20 minutes to dissolve. Cool and dilute up to the volume with diluent. 
 60 % Linearity sample concentration (30.0 mcg/mL of Diclofenac Sodium): 
Transfer 3.0 mL of above sample stock solution through pipette into 100 mL 
volumetric flask. Dilute up to the volume with diluent. Mix and filter the solution 
through 0.45 µm nylon filter and collect the solution in HPLC vial after discarding 
about first 2 mL of the filtrate. 
80 % Linearity sample concentration (40.0 mcg/mL of Diclofenac Sodium): 
Transfer 4.0 mL of above sample stock solution through pipette into 100 mL 
volumetric flask. Dilute up to the volume with diluent. Mix and filter the solution 
through 0.45 µm nylon filter and collect the solution in HPLC vial after discarding 
about first 2 mL of the filtrate. 
100 % Linearity sample concentration (50.0 mcg/mL of Diclofenac Sodium): 
Transfer 5.0 mL of above sample stock solution through pipette into 100 mL 
volumetric flask. Dilute up to the volume with diluent. Mix and filter the solution 
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through 0.45 µm nylon filter and collect the solution in HPLC vial after discarding 
about first 2 mL of the filtrate. 
120 % Linearity sample concentration (60 mcg/mL of Diclofenac Sodium): 
Transfer 6.0 mL of above sample stock solution through pipette into 100 mL 
volumetric flask. Dilute up to the volume with diluent. Mix and filter the solution 
through 0.45 µm nylon filter and collect the solution in HPLC vial after discarding 
about first 2 mL of the filtrate. 
160 % Linearity sample concentration (80.0 mcg/mL of Diclofenac Sodium): 
Transfer 8.0 mL of above sample stock solution through pipette into 100 mL 
volumetric flask. Dilute up to the volume with diluent. Mix and filter the solution 
through 0.45 µm nylon filter and collect the solution in HPLC vial after discarding 
about first 2 mL of the filtrate. 
 Injection sequence: 
Table No:7.4 
Different Linearity Standard and Sample 
preparations 
Number of 
Injection 
Blank 1 
Standard preparation 5 
60 % Linearity standard and sample 
concentration 
2 
80 % Linearity standard and sample 
concentration 
2 
100 % Linearity standard and sample 
concentration 
2 
120 % Linearity standard and sample 2 
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concentration 
160 % Linearity standard and sample 
concentration 
2 
Bracketing Standard 1 
 
Acceptance criteria: 
 Correlation co-efficient between concentrations and its area should be more 
than    0.998. 
 Report the Regression co-efficient. 
 Report the residual sum of squares. 
 Report the intercept. 
 Report the slope of the regression line. 
 Report the linearity graph. 
LINEARITY REPORT: 
The linearity response of Diclofenac Sodium was determined across the range are 
given in the following tables. The result shown in the table and its graphical   
Table No:7.5 
S.No. Parameter 
Results 
obtained 
Acceptance 
criteria 
01 Tailing factor  1.30 NMT 2.0 
02 Theoretical Plates  8203 NLT 2000 
03 %RSD  0.082 NMT 2.0 % 
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Linearity data obtained from 60 % to 160 % for Standard: 
Table No:7.6 
  
 
.Linearity graph obtained for Standard: 
Table No:7.7 
 
 
 
 
 
 
y = 34235x + 22726
R² = 0.9999
0
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LINEARITY OF DICLOFENAC SODIUM FOR STANDARD
Linearity level 
concentration 
in % 
Concentration 
in   (mcg/mL) 
Standard 
area -1 
Standard 
area-2 
Average area 
60 30 10510134 10517466 10513800 
80 40 13888541 13913995 13901268 
100 50 17375825 17338125 17356975 
120 60 20736432 20764499 20750466 
160 80 27622578 27628150 27625364 
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Linearity data obtained from 60% to 160% for Sample: 
 
Table No:7.8 
 
 
 
 
 
 
 
 
 
Linearity graph obtained for Sample: 
Table No:7.9 
 
 
 
 
y = 33088x + 43932
R² = 0.9999
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LINEARITY OF DICLOFENAC SODIUM FOR SAMPLE
Linearity 
level 
concentratio
n in % 
Concentratio
n in    
(mcg/mL) 
Sample 
area -1 
Sample 
area-2 
Average 
area 
60 30 10380500 10389220 10384860 
80 40 13779199 13647543 13713371 
100 50 16938975 16959321 16949148 
120 60 20221767 20214573 20218170 
160 80 26979686 26940612 26960149 
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Linearity results for Standard and Sample: 
Table No:7.10 
S. 
No. 
Parameter 
Results obtained Acceptance 
criteria Standard Sample 
01 Correlation coefficient 0.99999 0.99997 NLT 0.998 
02 Regression coefficient 0.99999 0.99993 Informative 
03 Residual sum of squares 1224830679.61 
11055132717.0
3 Informative 
04 Intercept 227263.8243 439328.1622 Informative 
05 Slope of regression line 342352.1284 330880.9892 Informative 
 
PRECISION 
 (ICH Harmonized Tripartite Guidelines  2005) Precision is the measure of the 
repeatability of result. 
The precision of an analytical procedure expresses the closeness of agreement 
between a series of measurements under the prescribed conditions. 
SYSTEM PRECISION: 
Determines the closeness of agreement of the same homogenous standard 
preparations under     the prescribe conditions.   
Procedure:   
Inject the blank, standard preparations based on “Injection sequence” detailed below 
and measure the corresponding area. 
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 Injection sequence: 
Table No:7.11 
Particulars Number of Injection 
Blank  1 
Standard preparation 6 
    Acceptance criteria: 
 The Tailing factor of the peak due to Diclofenac Sodium obtained from five 
replicates standard solution injections should be not more than 2.0. 
 Theoretical plates of the peak obtained for five replicates standard solution 
injections of Diclofenac Sodium should be not less than 2000. 
 The relative standard deviation of the area obtained for Five replicate standard 
solution of Diclofenac Sodium should be not more than 2.0%. 
 The relative standard deviation of the retention time obtained for five replicate 
standard solution of Diclofenac Sodium should be not more than 1.0%. 
   SYSTEM PRECISION REPORT: 
    System suitability results: 
Table No:7.12 
S.No. Parameter 
Results 
obtained 
Acceptance 
criteria 
01 Tailing factor  1.30 NMT 2.0 
02 Theoretical Plates  8483 NLT 2000 
03 
% RSD of area for five standard 
injections 
0.055 NMT 2.0 % 
04 
% RSD of retention time for five 
standard injections 
0.03 NMT 1.0 % 
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System precision Result in standard solution:  
Table No:7.13 
S. No. 
 
Retention time  
Standard 
area 
Tailing 
factor  
Theoretical 
plates  
01 6.827 16847470 1.31 8472 
02 6.830 16824096 1.30 8472 
03 6.830 16846315 1.29 8476 
04 6.830 16835165 1.29 8485 
05 6.830 16846787 1.30 8498 
06 6.833 16836738 1.29 8492 
Mean 6.830 16839429 1.30 8483 
Std dev 0.002 9238.39 
NMT 2.0 NLT 2000 (RSD 0.03 0.055 
Limit NMT 1.0 % NMT 2.0 % 
 
METHOD PRECISION (REPEATABILITY): 
Determines the closeness of agreement of the same homogenous sample under the 
prescribe conditions. Performing assay of Diclofenac Sodium Soft gelatin Capsules 
50 mg a minimum of six sample preparations from a single batch shall be made and 
analyze separately. 
Procedure:   
Inject the blank, standard and sample preparations based on “Injection sequence” 
detailed below and measure the corresponding area. 
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Injection sequence:  
Table No:7.14 
Particulars Number of Injection 
Blank  1 
Standard preparation 6 
Sample preparations – 1,2,3,4,5,6 2 
Bracketing standard 1 
 
Acceptance criteria: 
 Assay obtained for each six sample preparations should be between 90.0 and 
110% 
 The RSD obtained for the assay results for six sample preparations should be 
not   more   than 2.0 %.    
 
METHOD PRECISION (REPEATABILITY) REPORT: 
The Method precision was determined by preparing six sample solutions of Diclofenac 
Sodium from Diclofenac Sodium Soft gelatin Capsules 50 mg as per the procedure 
included in the protocol. 
System suitability Result in standard solution: 
Table No:7.15 
S.N
o. 
Parameter 
Results 
obtained 
Acceptance 
criteria 
01 Tailing factor  1.29 NMT 2.0 
02 Theoretical Plates  8472 NLT 2000 
03 %RSD  0.357 NMT 2.0 % 
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Method Precision results:  
Table No:7.16 
No. of 
Sample       
preparation 
Samples Area 
Results 
obtained % 
of drug 
Acceptance 
criteria 
Sample -1 Sample -2 Average  % of drug  
01 16614927 16856159 16735543 99.56 
90
.0
%
 - 
11
0.
0%
 
02 16576480 16608884 16592682 98.86 
03 16594408 16582746 16588577 98.74 
04 17001470 17012613 17007042 101.24 
05 17041613 17046783 17044198 101.40 
06 16408934 16414578 16411756 97.80 
Mean 
Std. Dev 
RSD 
99.60 
1.446 
1.452 NMT 2.0 % 
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ACCURACY (ICH Harmonized Tripartite Guidelines, 2005) 
 
 
Accuracy is defined as closeness of measured value to the true value 
 
 
The accuracy of an analytical procedure expresses the closeness of agreement between 
the value which is accepted either as a conventional true value or an accepted 
reference value and the value found. 
 
Preparation of analytical solution: 
Preparation of standard solution (50.0 mcg/mL of Diclofenac Sodium): 
Weigh accurately about 50 mg of Diclofenac Sodium working standard and transfer 
into 50 mL volumetric flask, add 30 mL of diluent and sonicate for 5 minutes to 
dissolve. Cool and dilute up to the volume with diluent and mix well. Transfer 5 mL of 
the above solution through pipette into 100 mL volumetric flask and dilute up to the 
volume with diluent. Mix and filter the solution through 0.45 µm nylon filter and 
collect the solution in HPLC vial after discarding about first 2 mL of the filtrate. 
Placebo spiked with 50 % standard preparation (25.0 mcg/mL of Diclofenac 
Sodium): 
Weigh accurately 5 Diclofenac Sodium Placebo capsules and 125 mg of Diclofenac 
Sodium Working standard and transfer into 250 mL volumetric flask. Add about 25 
mL of water and sonicate for 20 minutes to disperse the capsules shell. Add about 120 
mL of diluent and sonicate for 20 minutes to dissolve. Cool and dilute up to the 
volume with diluent and mix well. Transfer 5 mL of the above solution through pipette 
into 100 mL volumetric flask and dilute up to the volume with diluent. Mix and filter 
the solution through 0.45 µm nylon filter and collect the solution in HPLC vial after 
discarding about first 2 mL of the filtrate. Prepare the sample preparation in triplicate. 
 
Placebo spiked with 100 % standard preparation (50.0 mcg/mL of Diclofenac 
Sodium): 
Weigh accurately 5 Diclofenac Sodium Placebo capsules and 250 mg of Diclofenac 
Sodium Working standard and transfer into 250 mL volumetric flask. Add about 25 
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mL of water and sonicate for 20 minutes to disperse the capsules shell. Add about 120 
mL of diluent and sonicate for 20 minutes to dissolve. Cool and dilute up to the 
volume with diluent and mix well. Transfer 5 mL of the above solution through pipette 
into 100 mL volumetric flask and dilute up to the volume with diluent. Mix and filter 
the solution through 0.45 µm nylon filter and collect the solution in HPLC vial after 
discarding about first 2 mL of the filtrate. Prepare the sample preparation in triplicate. 
 
Placebo spiked with 150 % standard preparation (75.0 mcg/mL of Diclofenac 
Sodium): 
Weigh accurately 5 Diclofenac Sodium Placebo capsules and 375 mg of Diclofenac 
Sodium Working standard and transfer into 250 mL volumetric flask. Add about 25 
mL of water and sonicate for 20 minutes to disperse the capsules shell. Add about 120 
mL of diluent and sonicate for 20 minutes to dissolve. Cool and dilute up to the 
volume with diluent and mix well. Transfer 5 mL of the above solution through pipette 
into 100 mL volumetric flask and dilute up to the volume with diluent. Mix and filter 
the solution through 0.45 µm nylon filter and collect the solution in HPLC vial after 
discarding about first 2 mL of the filtrate. Prepare the sample preparation in triplicate. 
Procedure: 
Inject the blank, standard and placebo spiked standard preparations based on 
“Injection sequence” detailed below and measure the corresponding area. 
 
Injection sequence Table: 
Table No:7.17 
Particulars No.  of  injections 
Blank 1 
Standard preparation  6 
Placebo spiked standard solution 50% - 
preparations 1, 2 & 3 
Each 3 
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Placebo spiked standard solution 100% - 
preparations 1, 2 & 3 
Each 3 
Placebo spiked standard solution 150% - 
preparations 1, 2 & 3 
Each 3 
Bracketing Standard 1 
 
Calculations for Diclofenac Sodium accuracy 
Step 1: Standard added in mg (Working standard solution) 
     Standard wt in mg            5           
=------------------------- X -----------       
             50                         100 
 
Step 2: Placebo spiked standard added in mg at 100% 
    Wt of spiked standard in mg         5   
=--------------------------------------- X --------- 
                 250                                 100                      
 
Step 3: Placebo spiked standard recovered in mg 
        Placebo spiked standard area X standard added in mg (Working standard solution) 
=-------------------------------------------------------------------------------------------------------    
                                Average area of working standard solution 
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Step 4: Recovery in percentage 
    Placebo spiked standard recovered in mg 
=----------------------------------------------------- X 100 
    Placebo spiked standard added in mg 
Acceptance criteria: 
In each concentration, the Diclofenac Sodium working standard spiked with placebo should 
be recovered between 98.0 % and 102.0 %. 
 
      ACCURACY REPORT: 
Diclofenac Sodium Working standard was spiked with the proposed weight of placebo 
between said ranges and studied for its recovery. This study was performed as per the 
procedure included in the protocol. 
System suitability Results:  
Table No:7.18 
S.No. Parameter 
Results 
obtained 
Acceptance 
criteria 
01 Tailing factor  1.28 NMT 2.0 
02 Theoretical Plates  8168 NLT 2000 
03 %RSD  0.065 NMT 2.0 % 
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Accuracy Results:  
Table No:7.19 
Accuracy 
Level in 
% 
Standard 
added in mg 
Standard 
recovered in mg 
% 
Recovered 
Acceptance 
criteria  
50 
0.024926 0.024852 99.70 
98
.0
 %
 - 
10
2.
0 
%
 
0.024900 0.024952 100.21 
0.024982 0.024782 99.20 
100 
0.049798 0.049287 98.97 
0.049822 0.049370 99.09 
0.049766 0.049355 99.17 
150 
0.074670 0.075058 100.52 
0.074724 0.074829 100.14 
0.074728 0.073916 98.91 
 
RUGGEDNESS (ICH Harmonized Tripartite Guidelines, 2005) 
 
 
Defined by USP, The Ruggedness is the degree of reproducibility of test results  
obtained  under  a  variety  of  conditions,  such  as  different  laboratories, analysts,  
instruments,  environmental  conditions,  operators  and  materials. Ruggedness is a 
measure of reproducibility of test results under normal, expected operational 
conditions from laboratory and from analyst to analyst. 
 
Procedure 
 
 
Working standard solutions and working sample solution were prepared by 
different analyst on different days. Solutions were injected as per the test 
method and chromatograms were recorded. 
Inject the blank, standard and sample solution preparations based on “Injection 
sequence” detailed below and measure the corresponding area. 
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Injection sequence: 
Table No:7.20 
 
Acceptance criteria: 
 Assay in % obtained for each six sample preparations should be between 90.0 
and 110 % 
 The RSD obtained for the assay results for six sample preparations should be 
not more than 2.0 %. 
  
INTERMEDIATE PRECISION-(RUGGEDNESS) REPORT: 
The Intermediate precision was determined by preparing six sample solutions of 
Diclofenac Sodium Soft gelatin Capsules 50 mg by a different analyst. 
System suitability results:  
Table No:7.21 
S.No. Parameter Results obtained 
Acceptance 
criteria 
01 Tailing factor for  0.97 NMT 2.0 
02 Theoretical Plates  3613 NLT 2000 
03 %RSD  0.365 NMT 2.0% 
 
 
 
Particulars Number of Injection 
Blank 1 
Standard preparation 5 
Sample preparations – 1, 2, 3   (Analyst 1 and 2) Each 2 
Bracketing   Standard 1 
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 Intermediate Precision Results: 
Table No:7.22 
   Analyst-01 
No. of 
Sample       
preparatio
n 
Samples Area Results obtained Acceptance 
criteria 
Sample -1 Sample -2 Average Percentage  
of drug(%)
01 136605033 136576585 136590809 99.46 
90
.0
%
 - 
11
0.
0%
 
02 135078128 135292523 135185326 98.36 
03 137355003 139342029 138348516 100.68 
 
99.5 
1.16 
1.17 NMT 2.0 % 
 
Table No:7.23 
Analyst-02 
No. of 
Sample       
preparatio
n 
Samples Area Results 
obtained 
Acceptance 
criteria 
 Sample -1 Sample -2 Average Percentage  
of drug(%) 
90
.0
%
 - 
11
0.
0%
 04 135391567 135866633 135629100 98.82 
05 133686975 133716375 133701675 97.4 
06 134637569 134608473 134623021 98 
 
98.07 
0.71 
0.73 NMT 2.0 % 
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ROBUSTNESS (ICH Harmonized Tripartite Guidelines, 2005) 
 
 
Robustness of an analytical method is measure of its capacity to remain unaffected 
by small but deliberate variation in method parameters. It provides information about 
the reliability of method. 
 
Determination 
 
 
The robustness of an analytical method is determined by analysis of aliquots of 
homogenous lots by differing physical parameters like flow rate and column 
temperature. 
 
Change in flow rate plus (1.2 mL/minute): 
For Chromatographic conditions, follow the method of analysis  except by changing the 
flow to 1.2 mL / minute instead of 1.0 mL / minute. 
 Change in flow rate minus (0.8 mL/minute): 
For Chromatographic conditions, follow the method of analysis except by changing the 
flow to 0.8 mL / minute instead of 1.0 mL / minute. 
Change in wavelength plus (256 nm): 
For Chromatographic conditions, follow the method of analysis except   by changing 
the wavelength to 256 nm instead of 254 nm. 
 Change in wavelength minus (252 nm): 
For Chromatographic conditions, follow the method of analysis except    by changing 
the wavelength to 252 nm instead of 254 nm. 
Acceptance criteria: 
   Assay obtained for each robustness parameter should be between 90.0 and 110.0 %. 
The combined RSD obtained for the assay result of an each robustness parameter and 
six assay results of method precision should be not more than 2.0 %.    
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       ROBUSTNESS REPORT: 
A deliberate plus and minus changes in the analytical method parameters such as in 
wavelength, and flow rate was altered and the assay analytical study done as per the 
protocol. 
System suitability results:  
Table No:7.24 
Robustness results obtained:  
Table No:7.25 
S.No Parameter Name 
Results obtained Acceptance 
criteria Drug obtained in % 
01 Wavelength Plus (256 nm) 99.70  
 
90
.0
%
 - 
11
0.
0%
 
 02 
Wavelength Minus (252 
nm) 99.44  
03 Flow rate Plus (1.2 mL) 100.18  
04 Flow rate Minus (0.8 mL) 99.84  
 
 
 
S.No. Parameter Name 
Results obtained 
Tailing 
factor 
Theoretical 
Plates Area (RSD) 
01 Wavelength Plus (256 nm) 1.29 8171 0.094 
02 
Wavelength Minus (252 
nm) 
1.28 8166 0.149 
03 Flow rate Plus (1.2 mL) 1.26 7676 0.216 
04 Flow rate Minus (0.8 mL) 1.30 8830 0.100 
Acceptance criteria NMT 2.0 NLT 2000 NMT 2.0% 
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Combined Method precision and Robustness results obtained:  
Table No:7.26 
S.No Parameter Name 
Results obtained Drug 
obtained  drug  in % 
Acceptance 
criteria 
01 Method precision - 1 99.56 
90
.0
%
 - 
11
0.
0%
 
02 Method precision - 2 98.86 
03 Method precision - 3 98.74 
04 Method precision - 4 101.24 
05 Method precision - 5 101.40 
06 Method precision - 6 97.80 
07 Wavelength Plus (256 nm) 99.70 
08 Wavelength Minus (252 nm) 99.44 
09 Flow rate Plus (1.2 mL) 100.18 
10 Flow rate Minus (0.8 mL) 99.84 
Mean 99.68 
Std Dev 1.10 
% RSD 1.10 NMT 2.0% 
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STABILITY STUDIES (ICH Harmonized Tripartite Guidelines, 2005) 
 
 
Stability of the sample and  standard  solutions used  in  HPLC  method  is 
required  to  generate reproducible and  reliable results. The sample and  standard 
solutions  were  subjected  to  short  term  stability  studies  at  room  temperature. 
Stability studies were carried out initially, at 8 hours and 16 hours, 24 hours  time 
lapse of solution preparation. This study should be performed by injecting standard 
solution and sample solution at probable time points, and minimum not less than 24 
hours shall be studied. 
Note:  
Maintain the chromatographic conditions and solutions preparation as per the 
procedure given in method of analysis and injections sequence for solution stability 
study is given in below table. 
 
The maximum time for inject able usage of standard and sample solution is absolutely 
depends on the X Hours of solutions stability studied. 
Injection sequence:  
Table No:7.27 
Particulars Number of Injections 
Blank  (0 Hour) 1 
Standard preparation (0 Hour) 1 
Sample preparation  (0 Hour) 1 
Blank  (X Hours) 1 
Standard preparation (X Hours) 1 
Sample preparation  (X Hours) 1 
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Acceptance criteria: 
Cumulative % RSD for area obtained between initial time point and various probable 
intervals time points should be not more than 2.0 %. 
 
STABILITY OF ANALYTICAL SOLUTIONS: 
Standard and sample solutions to be used in the analytical method are scrutinized for 
their solution’s stability. This study was performed by injecting standard and sample 
solution for the period of 24 hours.  
 
System suitability results and Cumulative % RSD results obtained for Stability of 
standard solution:  
Table No :7.28 
S. No. Time point 
Standard 
solution area 
Results obtained 
Cumulative 
% RSD 
Tailing 
factor  
Theoretical 
plate  
01 0th hour 16777065 NA 1.33 7924 
02 4
th hour 16781531 0.019 1.34 7984 
03 8th hour 16831375 0.179 1.33 7951 
04 12th hour 16849225 0.214 1.35 8012 
05 16th hour 16978143 0.484 1.35 7951 
06 20th hour 16988890 0.557 1.36 7936 
07 24th hour 17135284 0.785 1.36 7923 
Limit NMT 2.0 % NMT 2.0 NLT 2000 
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System suitability results and Cumulative % RSD results obtained for Stability 
of sample solution:  
Table No:7.29 
S. No. Time point Standard solution area 
Results obtained 
Cumulativ
e % RSD 
Tailing 
factor  
Theoretical 
plate  
01 0th hour 16682977 NA 1.33 7922 
02 4
th hour 16691317 0.035 1.34 7969 
03 8th hour 16697379 0.043 1.35 7940 
04 12th hour 16717797 0.089 1.36 8009 
05 16th hour 16688628 0.080 1.35 7950 
06 20th hour 16702950 0.074 1.35 7921 
07 24th hour 16695481 0.068 1.35 7905 
Limit 
NMT 2.0 
% 
NMT 2.0 NLT 2000 
 
LIMIT OF DETECTION (ICH Harmonized Tripartite Guidelines, 2005) 
 
 
Limit of detection is the lowest concentration of the analyte that can be detected by 
injecting decreasing amount, not necessarily quantity by the method, under the 
stated experimental conditions. The minimum concentration at which the analyte 
can be detected  is determined from the linearity curve by applying the 
formula. 
 
LOD        =    3.3 SD/slope. 
 
The lowest concentration of  Diclofenac sodium hat can be detected was 
determined from standard curve was 0.77 µg/ml. 
LIMIT OF QUANTITATION (ICH Harmonized Tripartite Guidelines, 2005) 
 
 
Limit of quantitation is the lowest concentration of the analyte in a sample that can 
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be estimated quantitatively by injecting decreasing amount of drug with acceptable 
precision and accuracy under the stated experimental conditions of the method. 
Limit of quantitation can be obtained from linearity curve by applying the following 
formula. 
 
LOQ   = 10 SD/ slope. 
 
 
The lowest concentration at which peak can be quantified is called LOQ. It was 
found to be 2.34µg/ml for Diclofenac Sodium. 
 
 
 
Table No: 7.30 
  
  
Sample 
 
LOD 
 
LOQ 
 
Diclofenac 
sodium 
0.77 µ g/ml. 
 
2.34µ g/ml. 
 
 
ASSAY RESULTS 
PROCEDURE 
Separately Blank, Standard and test preparation was injected into liquid 
chromatogram and the areas for major peaks were recorded by using the following 
formula. 
   
 
Calculation 
 
 
Sample area × sample dilution × purity of working standard × Average weight×100X 
Convertion factor    
Standard area × standard dilution × Label claim х100 
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Assay result for Replicate injection 
 
Table No: 7.31 
 
 
Inj. No. Area of Diclofenac 
sodium 
 
 
w/w % Diclofenac sodium 
Recovered 
1 16735543 99.56 
2 16592682 98.86 
3 16588577 98.74 
Mean 16638934 99.05 
S.D 83691.0205 0.44287 
%R.S.D 0.50 0.45 
 
 
 
RESULT 
 
 
The mean recovery for assay results was found to be    97 – 99w/w % for 
 
Diclofenac sodium
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8.CHROMATOGRAMS 
 
              Specificity   ( Blank, Standard & Sample) 
Chromatogram No – 8.1 
 
Blank 
  
Chromatogram No 8.2 
 
Placebo 
 
 
Chromatogram No – 8.3 
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Standard (Replicate no-1) 
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Chromatogram No – 8.4 
 
 Standard (Replicate no-2) 
 
 
                                              
Chromatogram No – 8.5 
 
 Standard (Replicate no-3) 
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Chromatogram No – 8.6 
 
 Standard (Replicate no-4) 
 
 
 
Chromatogram No – 8.7 
 
 Standard (Replicate no-5) 
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Chromatogram No – 8.8 
 
  Sample (Replicate no-1) 
 
 
Chromatogram No – 8.9 
 
  Sample (Replicate no-2) 
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Chromatogram No – 8.10 
 
   Bracketing standard  
 
 
 
 
 
LINEARITY AND RANGE  
 
(Blank, Standards, linearity samples 60% ,80%,100%120%160%) 
 
  
 
Chromatogram No – 8.11 
  
Blank 
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Chromatogram No – 8.12 
 
Standard (Replicate no-1) 
 
 
Chromatogram No – 8.13 
 
Standard (Replicate no-2) 
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Chromatogram No – 8.14 
 
Standard (Replicate no-3) 
 
 
 
 
Chromatogram No – 8.15 
 
Standard (Replicate no-4) 
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Chromatogram No – 8.16 
 
Standard (Replicate no-5) 
 
 
Chromatogram No – 8.17 
 
Linearity 60%(Replicate no-1) 
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Chromatogram No – 8.18 
 
Linearity 60%(Replicate no-2) 
 
 
Chromatogram No – 8.19 
 
Linearity 80%(Replicate no-1) 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter-8 Chromatograms 
Dept. of Pharmaceutical Analysis J.K.K . Nattraja College Of Pharmacy 
94 
 
 
 
Chromatogram No – 8.20 
 
Linearity 80%(Replicate no-2) 
 
 
 
 
 
 
Chromatogram No – 8.21 
 
Linearity 100%(Replicate no-1) 
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Chromatogram No – 8.22 
 
Linearity 100%(Replicate no-2) 
 
 
 
Chromatogram No – 8.23 
 
Linearity 120%(Replicate no-1) 
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Chromatogram No – 8.24 
 
Linearity 120%(Replicate no-2) 
 
 
Chromatogram No – 8.25 
 
Linearity 160%(Replicate no-1) 
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Chromatogram No – 8.26 
 
Linearity 160%(Replicate no-2) 
 
 
 
Chromatogram No – 8.27 
 
Bracketing standard 
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PRECISION-SYSTEM PRECISION  
 
(Blank and standards) 
Chromatogram No – 8.28 
 
Blank 
 
Chromatogram No – 8.29 
 
System precision (Replicate no-1) 
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Chromatogram No – 8.30 
 
System precision (Replicate no-2) 
 
 
Chromatogram No – 8.31 
 
System precision (Replicate no-3) 
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Chromatogram No – 8.32 
 
System precision (Replicate no-4) 
 
 
 
 
 
Chromatogram No – 8.33 
 
System precision (Replicate no-5) 
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PRECISION-METHOD  PRECISION  
 
(Blank ,standards, Sample preparations 1,2,3,4,5,6) 
 
Chromatogram No – 8.34 
 
Blank 
 
Chromatogram No – 8.35 
 
Standard (Replicate no-1) 
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Chromatogram No – 8.36 
 
Standard (Replicate no-2) 
 
 
Chromatogram No – 8.37 
 
Standard (Replicate no-3) 
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Chromatogram No – 8.38 
 
Standard (Replicate no-4) 
 
 
  
 
 
Chromatogram No – 8.39 
 
Standard (Replicate no-5) 
 
 
 
 
 
 
 
 
Dept. of Pharmaceutical Analysis J.K.K . Nattraja College Of Pharmacy 
104 
 
Chapter-9 Results And Discussion  
 
Chromatogram No – 8.40 
 
Method precision-01 (Replicate no-1) 
 
 
Chromatogram No – 8.41 
 
Method precision-01 (Replicate no-2) 
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Chromatogram No – 8.42 
 
Method precision-02 (Replicate no-1) 
 
   
Chromatogram No – 8.43 
 
Method precision-02 (Replicate no-2) 
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Chromatogram No – 8.43 
 
Method precision-03 (Replicate no-1) 
 
 
                                                       Chromatogram No – 8.44 
 
Method precision-03 (Replicate no-2) 
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Chromatogram No – 8.45 
 
Method precision-04 (Replicate no-1) 
 
 
 
Chromatogram No – 8.46 
 
Method precision-04 (Replicate no-2) 
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Chromatogram No – 8.47 
 
Method precision-05 (Replicate no-1) 
 
 
Chromatogram No – 8.48 
 
Method precision-05 (Replicate no-2) 
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Chromatogram No – 8.49 
 
Method precision-06 (Replicate no-1) 
 
 
                                                         Chromatogram No – 8.50 
 
Method precision-06 (Replicate no-2) 
 
 
Chromatogram No – 8.51 
 
Bracketing standard 
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Accuracy 
Chromatogram No – 8.52 
 
Accuracy 50%-Preparation-1 (Replicate no-1) 
  
 
                                                        Chromatogram No – 8.53 
 
Accuracy 50%-Preparation-1 (Replicate no-2) 
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                    Chromatogram No – 8.54 
 
Accuracy 50%-Preparation-1 (Replicate no-3) 
 
 
 
Chromatogram No – 8.55 
 
Accuracy 50%-Preparation-2 (Replicate no-1) 
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                                                     Chromatogram No – 8.56 
 
Accuracy 50%-Preparation-2 (Replicate no-2) 
 
 
 
Chromatogram No – 8.57 
 
Accuracy 50%-Preparation-2 (Replicate no-3) 
 
 
 
Chromatogram No – 8.58 
 
Accuracy 50%-Preparation-3 (Replicate no-1) 
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Chromatogram No – 8.59 
 
Accuracy 50%-Preparation-3 (Replicate no-2) 
 
 
Chromatogram No – 8.60 
 
Accuracy 50%-Preparation-3 (Replicate no-3) 
 
 
 
Chromatogram No – 8.61 
 
Accuracy 100%-Preparation-1 (Replicate no-1) 
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Chromatogram No – 8.62 
 
Accuracy 100%-Preparation-1 (Replicate no-2) 
 
 
 
Chromatogram No – 8.63 
 
Accuracy 100%-Preparation-1 (Replicate no-3) 
 
 
 
Chromatogram No – 8.64 
 
Accuracy 100%-Preparation-2 (Replicate no-1) 
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Chromatogram No – 8.65 
 
Accuracy 100%-Preparation-2 (Replicate no-2) 
 
 
 
Chromatogram No – 8.66 
 
Accuracy 100%-Preparation-2 (Replicate no-3) 
 
 
 
Chromatogram No – 8.67 
 
Accuracy 100%-Preparation-3 (Replicate no-1) 
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Chromatogram No – 8.68 
 
Accuracy 100%-Preparation-3 (Replicate no-2) 
 
 
 
 
Chromatogram No – 8.69 
 
Accuracy 100%-Preparation-3 (Replicate no-3) 
 
 
 
Chromatogram No – 8.70 
 
Accuracy 150%-Preparation-1 (Replicate no-1) 
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Chromatogram No – 8.71 
 
Accuracy 150%-Preparation-1 (Replicate no-2) 
 
 
Chromatogram No – 8.72 
 
Accuracy 150%-Preparation-1 (Replicate no-3) 
 
 
 
Chromatogram No – 8.73 
 
Accuracy 150%-Preparation-2 (Replicate no-1) 
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Chromatogram No – 8.74 
 
Accuracy 150%-Preparation-2 (Replicate no-2) 
 
 
Chromatogram No – 8.75 
 
Accuracy 150%-Preparation-2 (Replicate no-3) 
 
 
 
Chromatogram No – 8.76 
 
Accuracy 150%-Preparation-3 (Replicate no-1) 
 
 
  
Dept. of Pharmaceutical Analysis J.K.K . Nattraja College Of Pharmacy 
119 
 
Chapter-9 Results And Discussion  
 
Chromatogram No – 8.77 
 
Accuracy 150%-Preparation-3 (Replicate no-2) 
 
 
Chromatogram No – 8.78 
 
Accuracy 150%-Preparation-3 (Replicate no-3) 
 
 
 
RUGGEDNESS 
 
(Blank ,standards, Sample preparations 1,2,3,4,5,6) 
 
Chromatogram No – 8.78 
 
Blank 
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Chromatogram No – 8.79 
 
Standard (Replicate no-1) 
 
 
 
Chromatogram No – 8.80 
 
Standard (Replicate no-2)  
Chromatogram No – 8.81 
 
Standard (Replicate no-3) 
 
 
  
Dept. of Pharmaceutical Analysis J.K.K . Nattraja College Of Pharmacy 
121 
 
Chapter-9 Results And Discussion  
 
Chromatogram No – 8.82 
 
Standard (Replicate no-4) 
 
 
 
 
Chromatogram No – 8.83 
 
Standard (Replicate no-5) 
  
 
Chromatogram No – 8.84 
 
Sample-01 (Replicate no-1) 
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Chromatogram No – 8.85 
 
Sample-01 (Replicate no-2) 
  
 
 
Chromatogram No – 8.86 
 
Sample-02 (Replicate no-1) 
  
 
Chromatogram No – 8.87 
 
Sample-02 (Replicate no-2) 
  
 
  
Dept. of Pharmaceutical Analysis J.K.K . Nattraja College Of Pharmacy 
123 
 
Chapter-9 Results And Discussion  
 
Chromatogram No – 8.88 
 
Sample-03 (Replicate no-1) 
  
 
 
Chromatogram No – 8.89 
 
      Sample-03 (Replicate no-2) 
  
 
Chromatogram No – 8.90 
 
Sample-04 (Replicate no-1) 
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                                                           Chromatogram No – 8.91 
 
Sample-04 (Replicate no-2) 
  
 
 
Chromatogram No – 8.92 
 
Sample-05 (Replicate no-1) 
 
 
Chromatogram No – 8.93 
 
Sample-05 (Replicate no-2) 
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                                                          Chromatogram No – 8.94 
 
Sample-06 (Replicate no-1) 
  
 
Chromatogram No – 8.95 
 
Sample-06 (Replicate no-2) 
 
 
Chromatogram No – 8.96 
 
Bracketing standard 
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ROBUSTNESS 
Chromatogram No – 8.97 
 
Change in the wave length -256nm Blank 
 
 
Chromatogram No – 8.98 
 
Change in the wave length -256nm Standard 
Replicate no-1 
 
 
Chromatogram No – 8.99 
 
Change in the wave length -256nm Standard 
Replicate no-2 
 
 
    
Chromatogram No – 8.100 
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Change in the wave length -256nm Standard 
Replicate no-3 
 
 
Chromatogram No – 8.101 
 
Change in the wave length -256nm Standard 
Replicate no-4 
 
Chromatogram No – 8.102 
 
Change in the wave length -256nm Standard 
Replicate no-5 
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Chromatogram No – 8.103 
 
Change in the wave length -256nm Sample  Replicate 
no-1 
 
 
Chromatogram No – 8.104 
 
Change in the wave length -256nm Sample  Replicate 
no-2 
 
Chromatogram No – 8.105 
 
Change in the wave length -256nm Bracketing 
standard 
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Chromatogram No – 8.106 
 
Change in the wave length -252nm Blank 
 
 
Chromatogram No – 8.107 
 
Change in the wave length -252nm Standard 
Replicate no-1 
 
 
 
 
Chromatogram No – 8.108 
 
Change in the wave length -252nm Standard 
Replicate no-2 
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Chromatogram No – 8.109 
 
Change in the wave length -252nm Standard 
Replicate no-3 
 
 
Chromatogram No – 8.110 
 
Change in the wave length -252nm Standard 
Replicate no-4 
 
Chromatogram No – 8.111 
 
Change in the wave length -252nm Standard 
Replicate no-5 
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Chromatogram No – 8.112 
 
Change in the wave length -252nm Sample Replicate 
no-1 
 
 
Chromatogram No – 8.113 
Change in the wave length -252nm Sample Replicate 
no-2 
 
Chromatogram No – 8.114 
 
Change in the wave length -252nm Bracketing 
standard 
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Chromatogram No – 8.115 
 
Change in the flow rate -1.2ml  Blank 
 
 
Chromatogram No – 8.116 
 
Change in the flow rate -1.2ml  Standard Replicate 
no-1 
 
Chromatogram No – 8.117 
 
Change in the flow rate -1.2ml  Standard Replicate 
no-2 
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Chromatogram No – 8.118 
 
Change in the flow rate -1.2ml  Standard Replicate 
no-3 
 
 
Chromatogram No – 8.119 
 
Change in the flow rate -1.2ml  Standard Replicate 
no-4 
 
Chromatogram No – 8.120 
 
Change in the flow rate -1.2ml  Standard Replicate 
no-5 
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Chromatogram No – 8.121 
 
Change in the flow rate -1.2ml  Sample  
Replicate no-1 
 
Chromatogram No – 8.122 
 
Change in the flow rate -1.2ml  Sample  Replicate no-
2 
 
Chromatogram No – 8.123 
 
Change in the flow rate -1.2ml  Bracketing standard 
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Chromatogram No – 8.124 
 
Change in the flow rate -0.8ml  Blank 
 
 
 
Chromatogram No – 8.125 
 
Change in the flow rate -0.8ml  
Standard Replicate-01 
 
 
 
Chromatogram No – 8.126 
 
Change in the flow rate -0.8ml   
Standard Replicate-02 
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Chromatogram No – 8.127 
 
Change in the flow rate -0.8ml  
Standard Replicate-03 
 
 
 
Chromatogram No – 8.128 
 
Change in the flow rate -0.8ml   
Standard Replicate-04 
 
 
Chromatogram No – 8.129 
 
Change in the flow rate -0.8ml   
Standard Replicate-05 
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Chromatogram No – 8.130 
 
Change in the flow rate -0.8ml   
Sample Replicate-01 
 
 
Chromatogram No – 8.131 
 
Change in the flow rate -0.8ml  . 
Sample Replicate-02 
 
 
Chromatogram No – 8.132 
 
Change in the flow rate -0.8ml  
Bracketing standard 
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Stability studies 
Chromatogram No – 8.133 
 
0 hour  Blank 
 
 
Chromatogram No – 8.134 
 
0 hour  Standard 
 
 
 
Chromatogram No – 8.135 
 
0 hour  Sample 
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Chromatogram No – 8.136 
 
4th  hour  Blank 
  
 
 
Chromatogram No – 8.137 
 
4th  hour  Standard 
  
 
Chromatogram No – 8.138 
 
4th   hour  Sample 
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Chromatogram No – 8.139 
 
8th   hour  Blank 
 
 
 
Chromatogram No – 8.140 
 
8th   hour  Standard 
 
 
 
Chromatogram No – 8.141 
 
8th   hour  Sample 
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Chromatogram No – 8.142 
 
12th   hour  Blank 
 
 
 
Chromatogram No – 8.143 
 
12th   hour  Standard 
 
 
 
Chromatogram No – 8.144 
 
12th   hour  Sample 
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Chromatogram No – 8.145 
 
16th   hour  Blank 
 
 
 
Chromatogram No – 8.146 
 
16th   hour  Standard 
  
 
 
Chromatogram No – 8.147 
 
16th   hour  Sample 
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Chromatogram No – 8.148 
 
20th   hour  Blank 
  
 
 
Chromatogram No – 8.149 
 
20th   hour  Standard 
  
 
Chromatogram No – 8.150 
 
20th   hour  Sample 
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Chromatogram No – 8.151 
 
24th   hour  Blank 
  
 
 
Chromatogram No – 8.152 
 
24th   hour  Standard 
  
 
Chromatogram No – 8.153 
 
24th   hour  Sample 
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  RESULTS AND DISCUSSION 
  
 
A new isocratic reverse-phase high performance liquid chromatographic with UV-
detection   at   254   nm   was   developed   for   quantitative   determination   of 
Diclofenac Sodium in Pharmaceutical soft gelatin capsule dosage forms. The mobile 
phase used was of 400 volume of buffer  (6.8 g of Potassium dihydrogen orthophosphate 
in 1000 mL of water and then adjust the pH to 3.00 with dilute Orthophosphoric acid.) 
and 600 volume of Acetonitrile . The chromatographic method was performed on C18, 
15 cm x 4.6-mm, 5µm column at a flow rate of 1 ml/min. Column Temperature was 
set a 25ºC and injection volume was 20µl. 
 
Estimation  of  Diclofenac Sodium in  Pharmaceutical  soft gelatin capsule dosage 
form dosage forms by RP-HPLC method was carried out using optimized 
chromatographic conditions. The standard and sample solutions were prepared. The 
chromatograms were recorded. The peak area ratio of standard and sample solutions was 
calculated. The capsule shows percentage purity values ranging from 97% to 99%  for 
Diclofenac Sodium  respectively. 
 
The method was validated according to the Q2 specifications of the ICH 
guidelines. The validated parameters were system suitability, Precision, Accuracy, 
Specificity, linearity, Ruggedness Robustness and. LOD, LOQ. 
 
The  resulting  chromatograms  exhibited  retention  time  at  6.50  min   
for Diclofenac Sodium .The number of theoretical plates were more than 2000, for 
Diclofenac Sodium  it was 8496  respectively. The tailing factor was less than 2 that is 
1.29 for Diclofenac Sodium  .  Hence all the system suitability parameters were with the 
specified limits.  
 
The specificity of the method was established by injecting blank, placebo and standard . 
It was observed that there was no interference caused due to the placebo. Results were 
presented in Table 7.2 and figure was shown in Chromatogram No. 8.1 - 8.10. 
 
Dept. of Pharmaceutical Analysis J.K.K . Nattraja College Of Pharmacy 
146 
 
Chapter-9 Results And Discussion  
 
System suitability result passes and the results obtained for specificity are found within 
the acceptance criteria. The obtained results proved that there will not be blank and 
placebo interference in the Diclofenac Sodium  peak by this assay method. The linearity 
for the drugs from concentration range of 30 - 80 µ g/ml was established by constructing 
the calibration curve with concentration on x-axis and peak area on y-axis with the 
correlation coefficient of 0.999 for the drug which were within specified limits. Results 
were shown in Table 7.6 - 7.10 and Chromatogram No. 8.1 -  8.27.  
 
System suitability result passes and the results obtained for linearity are found within the 
acceptance criteria. Hence it is concluded that the range of concentrations, 60 % to 160 % 
with respect to 100 % working concentration for assay method is linear for Diclofenac 
Sodium  . 
 
System  Precision  was  determined  by preparing  the  standard  solution  at working 
concentration and analysis was carried for six replicate injections. The percentage relative 
standard deviation (% RSD) was calculated for the peak areas of Diclofenac Sodium  
which was found to be 0.055 respectively which were within the acceptance criteria of 
not more than 2.0%. The percentage relative standard deviation (% RSD) was calculated 
for the peak retention time of Diclofenac Sodium which was found to be 0.03  
respectively which were within the acceptance criteria of not more than 1.0%.  Results 
were presented in Table 7.13 and figure were shown in Chromatogram No. 8.28  -  8.33 
All the system suitability parameters were well within the desirable limits, it indicates 
that the prescribed method is suitable to perform the estimation of Diclofenac Sodium 
from Diclofenac Sodium Soft gelatin Capsules 300 mg. Further there was no deviation in 
the given method 
 
Method  precision  was  determined  by  preparing  six  different  samples solutions from 
the capsules of same batch at working concentration and analysis was carried out for six 
replicate injections. The percentage relative standard deviation (% RSD) was calculated 
for the peak areas of Diclofenac Sodium which was found to be 1.452 for  the drug 
which is with in the acceptance criteria of not more than 2.0%. These results give the 
assurance of method repeatiility. Results were presented in Table 7.16 and figures 
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were shown in Chromatogram No. 8.34 -8.51 . 
 
System suitability parameters were well within the prescribed limits which revealed that 
the prescribed procedure is capable to perform Method precision using sample 
preparation. All the performed samples showed results between 90.0 % and 110.0 %.The 
Method precision parameter complies as per In-House specification. 
 
Accuracy of the method was determined by performing recovery studies at 
 
50%, 100%, 150%. Percentage recovery Diclofenac Sodium were found to be % of 
recovered with in  the range of 98.91% - 100.52% and mean of % recovered within the 
range of  99.08% - 99.86% respectively which were with in the acceptance criteria of 98 
- 102% respectively. Result of accuracy were shown in the Table 7.19 and figures were 
shown in Chromatogram No. 8.52 – 8.78. 
 
System suitability result passes and the results obtained for accuracy are found within the 
acceptance criteria. Hence, it is concluded that the assay method for Diclofenac Sodium 
Soft gelatin Capsules 50 mg is proficient to recover between 50 % and 150 % of 
Diclofenac Sodium drug material when spiked in placebo. 
 
Ruggedness was determined by performing the same assay by different analyst on the 
different days and the results were checked for the reproducibility. The  %RSD  was  
found  to  be  1.177  – 1.332  Diclofenac Sodium which were with in the acceptance 
range of not more than 2 %. Results of ruggedness were shown in Table 7.22 and 7.23 
and figures were shown in Chromatogram No. 8.78 – 8.90. 
 
System suitability result passes and the results obtained for Intermediate precision are 
found within the acceptance criteria. Combined Intermediate precision results and 
Method precision results are meets the prescribed limit as per In-House specification. 
Hence, it is concluded that the assay method is capable to generate, repeatable assay 
results for Diclofenac Sodium Soft gelatin Capsules 50 mg in multiple preparations of a 
unique batch, besides by a different analyst 
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The Robustness of the method was established changing the parameters like wave 
length and flow rate. The changes in system suitability parameters were with in the 
limits which ensures that the method developed can withstand slight changes in the 
experimental conditions and produce results with good reproducibility and repeatability. 
Results were presented in Table 7.24-7.26 and figures were shown in Chromatogram 
No. 8.97 – 8.132 
 
System suitability result passes in all the deliberately changed methods and the results 
obtained for all deliberately changed methods are found within the acceptance criteria. 
Combined deliberately changed methods results and Method precision results are well within 
the desirable limit. It is concluded that the deliberately changed assay methods results are 
remains unaffected in small variations which confirmed that all the methods are proficient to 
estimate Diclofenac Sodium in Diclofenac Sodium Soft gelatin Capsules 50 mg. 
Standard and sample solutions to be used in the analytical method are scrutinized for their 
solution’s stability. This study was performed by injecting standard and sample solution for 
the period of 24 hours.  
Stability Studies was carried out at  0,4,8,12,16,20 hours and 24 hours 
 
time lapse of solutions preparation. The %RSD for Diclofenac Sodium standard  were 
found to be with in the 0.019% and 0.785% and The %RSD for Diclofenac Sodium 
sample   were found to be with in the 0.035% and 0.080% which were with the 
acceptance criteria of not more than 2%. Results of stability were shown in Table 
7.28 and 7 . 2 9  a n d  figures were shown in Chromatogram No. 8.133 – 8.159. 
 
System suitability result passes and the results obtained for stability of standard solution and 
sample solution are found within the acceptance criteria for the minimum period of 24 hours 
study. 
The Limit of Detection (LOD) and Limit of Quantitation (LOQ) was determined 
by injecting progressively low concentrations of the standard solutions using the 
developed RP-HPLC method. The LOD is the smallest concentration of the  analyte  
that  gives  a  measurable  response  (signal  to  noise  ratio  of  3).The detection limit 
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(LOD) was found to be 0.77µ g/ml for Diclofenac Sodium respectively. 
 
The LOQ is the smallest concentration of the analyte, which gives response that 
can be accurately quantified (signal to noise ratio of 10).The quantitation limit (LOQ)  
was  found  to  be 2 . 3 4   µ g/ml  for  Diclofenac Sodium respectively. In case of LOD 
and LOQ the S/N ratio were found to be within the limits. Results of LOD and LOQ 
were parented in Table 7.30 . 
 
S.NO Parameter Specifications Inference 
 
1 
 
Specificity 
 
No interference No interference 
 
2 
 
Similarity factor 
 
0.98 – 1.02 
 
0.99 
 
3 
 
System precision 
 
Area of %RSD NMT 2.0 
 
0.30 
4 Method precision 
 
%RSD NMT 2.0 
 
1.45 
5 Linearity range 
 
Correlation coefficient 
NLT  0.999 
 
0.9999 
6 Accuracy 
 
% Mean Recovery 
98 –10 2 % 
98.91% - 
100.52% 
 
7 
 
Limit of Detection 
Signal noise ratio should be 
more than 
3:1 for the conc 
0.77µ g/ml 
8 Limit of Quantitation 
Signal noise ratio should be 
more than 
10:1 for the conc 
2.34µ g/ml 
 
9 
Robustness by 
Change in flow rate 
and 
columntemperature 
No effect on system suitability 
parameters 
No effect on 
system suitability 
parameters 
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10. SUMMARY AND CONCLUSION 
 
A RP-HPLC method is developed and validated as per ICH guidelines for 
simultaneous estimation of Diclofenac Sodium in soft gelatin dosage form. 
 
In present study an attempt has been made to modify experimental condition, in 
order to estimate the drugs. The mobile phase was selected after trying various 
combinations of polar solvents. The proportion of solvents and variation of buffers was 
found to be quite critical as slight variation in it adversely affected the resolution of 
peaks. Considering all the fact the following parameter were finally fixed for this method 
 
Chromatographic conditions: 
Equipment                                   : High performance liquid chromatography 
Column                   : C18, 15 cm x 4.6 mm, 5 µm  
Flow Rate                           : 1.0 mL/minute 
Pump mode       : Isocratic  
Detector wavelength                  : 254 nm 
Injection volume                 : 20 µL 
Column Temperature                 : 25.0˚C 
Sample Temperature                 : 20.0˚C 
Run time                                        :   7 Min 
The proposed method was found to be rapid, accurate, precise, specific, robust, 
rugged and economical. The mobile phase is simple to prepare and economical. The 
sample recoveries in all formulations were in good agreement with their respective label 
claims and they suggested non-interference of formulation excipients in the estimation. 
This method is also having an advantage than reported method that the retention time of 
the drugs is below 8 mins and the drugs can be assayed with the short time. Thus the 
method is not time consuming and can be used in laboratories for the routine analysis of 
combination drugs. 
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